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Abbreviations and acronyms
ABPM Ambulatory blood pressure monitoring
AF Atrial fibrillation
ARVC Arrhythmogenic right ventricular cardiomyopathy
ATP Adenosine triphosphate
AV Atrioventricular
AVID Antiarrhythmics versus Implantable
Defibrillators trial
BBB Bundle branch block
BNP B-type natriuretic peptide
BP Blood pressure
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b.p.m. Beats per minute
CI Confidence interval
CI-CSS Cardioinhibitory carotid sinus syndrome
CPG Committee for Practice Guidelines
CRT-D Cardiac resynchronization therapy defibrillator
CSM Carotid sinus massage
CSS Carotid sinus syndrome
DCM Dilated cardiomyopathy
DDD-PM Dual chamber pacemaker
ECG Electrocardiogram/electrocardiographic
ED Emergency department
EEG Electroencephalogram
EFAS European Federation of Autonomic Societies
EFIM European Federation of Internal Medicine
EHRA European Heart Rhythm Association
ENS European Neurological Society
EPS Electrophysiological study
ESC European Society of Cardiology
EUGMS European Union Geriatric Medicine Society
EuSEM European Society of Emergency Medicine
HBPM Home blood pressure monitoring
HCM Hypertrophic cardiomyopathy
HR Heart rate
ICD Implantable cardioverter defibrillator
ILR Implantable loop recorder
ISSUE International Study on Syncope of
Unknown Etiology
L-DOPA L-3,4-dihydroxyphenylalanine
LOC Loss of consciousness
LQTS Long QT syndrome
LVEF Left ventricular ejection fraction
MRI Magnetic resonance imaging
NYHA New York Heart Association
OH Orthostatic hypotension
PC-Trial Physical Counterpressure Manoeuvres Trial
PCM Physical counter-pressure manoeuvres
PNES Psychogenic non-epileptic seizures
POST Prevention of Syncope Trial
POTS Postural orthostatic tachycardia syndrome
PPS Psychogenic pseudosyncope
RCT Randomized controlled trial
SCD Sudden cardiac death
SNRT Sinus node recovery time
SU Syncope unit
SUP Syncope Unit Project
SVT Supraventricular tachycardia
TIA Transient ischaemic attack
t.i.d. Ter in die (three times daily)
TLOC Transient loss of consciousness
TNG Trinitroglycerin
VA Ventricular arrhythmia
VF Ventricular fibrillation
VT Ventricular tachycardia
VVS Vasovagal syncope
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in selecting the best management strat-
egies for an individual patient with a given condition. Guidelines and
their recommendations should facilitate decision making of health
professionals in their daily practice. However, the final decisions con-
cerning an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as
appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC), as well as by other soci-
eties and organisations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The rec-
ommendations for formulating and issuing ESC Guidelines can be
found on the ESC website (http://www.escardio.org/Guidelines-&-
Education/Clinical-Practice-Guidelines/Guidelines-development/Writ
ing-ESC-Guidelines). ESC Guidelines represent the official position of
the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC, including
representation from its relevant ESC sub-specialty groups, in order
to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management of a
given condition according to ESC Committee for Practice Guidelines
(CPG) policy. A critical evaluation of diagnostic and therapeutic pro-
cedures was performed, including assessment of the risk–benefit
ratio. The level of evidence and the strength of the recommendation
of particular management options were weighed and graded accord-
ing to predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declar-
ation of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
updated. The Task Force received its entire financial support from
the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate revisions
the Guidelines are approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for publica-
tion in the European Heart Journal. The Guidelines were developed
after careful consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing ESC Guidelines also includes the creation of
educational tools and implementation programmes for the recommen-
dations including condensed pocket guideline versions, summary slides,
booklets with essential messages, summary cards for non-specialists
and an electronic version for digital applications (smartphones, etc.).
These versions are abridged and thus, if needed, one should always
refer to the full-text version, which is freely available via the ESC
4 ESC Guidelines
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
website and hosted on the EHJ website. The National Societies of the
ESC are encouraged to endorse, translate and implement all ESC
Guidelines. Implementation programmes are needed because it has
been shown that the outcome of disease may be favourably influenced
by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC Guidelines fully
into account when exercising their clinical judgment, as well as in the
determination and the implementation of preventive, diagnostic, or
therapeutic medical strategies. However, the ESC Guidelines do not
override in any way whatsoever the individual responsibility of health
professionals to make appropriate and accurate decisions in consider-
ation of each patient’s health condition and in consultation with that pa-
tient or the patient’s caregiver where appropriate and/or necessary. It
is also the health professional’s responsibility to verify the rules and
regulations applicable to drugs and devices at the time of prescription.
2. Introduction
The first ESC Guidelines for the management of syncope were pub-
lished in 2001, with subsequent versions in 2004 and 2009. In March
2015, the ESC CPG considered that there were enough new data to
justify the production of new Guidelines.
The most important aspect characterizing this document is the
composition of the Task Force, which is truly multidisciplinary.
Cardiologists form a minority of the panel; experts in emergency
medicine, internal medicine and physiology, neurology and auto-
nomic diseases, geriatric medicine, and nursing cover all aspects of
management of the various forms of syncope and transient loss of
consciousness (TLOC).
Table 1 Classes of recommendations
Table 2 Levels of evidence
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.Compared with the previous versions of these Guidelines, the
2018 document contains Supplementary Data as an integral part.
While the print text mainly aims to give formal evidence-based rec-
ommendations according to the standardized rules of the ESC, this
new web-only feature allows expansion of the content to practical
issues, and aims to fill the gap between the best available scientific evi-
dence and the need for dissemination of these concepts into clinical
practice (‘We have the knowledge, we need to teach it’). Thanks to the
Supplementary Data further explanation on specific points is given,
and thanks to the Web Practical Instructions advice is given on how
to evaluate patients with loss of consciousness (LOC), and how to
perform and interpret tests properly; whenever possible, we provide
tracings, videos, flow charts, and checklists.
The document aims to be patient-orientated and focused on ther-
apy, and to reduce the risk of recurrence and the life-threatening
consequences of syncope recurrence. For this purpose, even in the
absence of strong evidence from trials, we give as much advice as
possible on the most appropriate therapy based on the practical ex-
pertise of the members of the Task Force (‘Our patients seek solutions,
not only explanations’). When possible, we provide therapeutic and
decision-making algorithms.
Finally, we recognize that one major challenge in syncope manage-
ment is the reduction of inappropriate admissions and inappropriate
use of tests while maintaining the safety of the patient. We give strong
focus to pathways and organizational issues (‘We have the knowledge;
we need to apply it’). In particular, we propose a care pathway for the
Figure 1 What is new in the 2018 syncope Guidelines? AA = antiarrhythmic; AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular car-
diomyopathy; CSM = carotid sinus massage; ECG = electrocardiogram; ED = emergency department; LVEF = left ventricular ejection fraction; EPS =
electrophysiological study; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
OH = orthostatic hypotension; PCM = physical counter-pressure manoeuvres; POTS = postural orthostatic tachycardia syndrome; PPS = psycho-
genic pseudosyncope; SNRT = sinus node recovery time; SU = syncope unit; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
6 ESC Guidelines
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..management of patients with TLOC from their arrival in the emer-
gency department (ED), and give practical instructions on how to set
up outpatient syncope clinics (syncope units) aimed at reducing hos-
pitalization, under- and misdiagnoses, and costs.
2.1 What is new in the 2018 version?
The changes in recommendations made in the 2018 version com-
pared with the 2009 version, the new recommendations, and the
most important new/revised concepts are summarized in Figure 1.
3. Definitions, classification, and
pathophysiology
3.1 Definitions
• Syncope is defined as TLOC due to cerebral hypoperfusion, char-
acterized by a rapid onset, short duration, and spontaneous com-
plete recovery.
Syncope shares many clinical features with other disorders; it
therefore presents in many differential diagnoses. This group of dis-
orders is labelled TLOC.
• TLOC is defined as a state of real or apparent LOC with loss of
awareness, characterized by amnesia for the period of uncon-
sciousness, abnormal motor control, loss of responsiveness, and
a short duration.
The two main groups of TLOC are ‘TLOC due to head trauma’
and ‘non-traumatic TLOC’ (Figure 2). Traumatic TLOC will not be
considered further in this document, so TLOC will be used to mean
non-traumatic TLOC.
The clinical features characterizing TLOC are usually derived from his-
tory taking from patients and eyewitnesses. Specific characteristics that
aid diagnosis are outlined in section 3 of the Web Practical Instructions.
TLOC groups are defined using pathophysiology: the qualifying cri-
terion for syncope is cerebral hypoperfusion; for epileptic seizures, it
is abnormal excessive brain activity; and for psychogenic TLOC it is
the psychological process of conversion. The syncope definition rests
on pathophysiology because no set of clinical features encompasses
all forms of syncope while also excluding all epileptic seizures and
psychogenic TLOC events.
• The adjective presyncope is used to indicate symptoms and signs
that occur before unconsciousness in syncope. Note that the
noun presyncope is often used to describe a state that resembles
the prodrome of syncope, but which is not followed by LOC.
Central illustration New/revised concepts in the management of syncope. ECG = electrocardiogram; ED = emergency department; ICD =
implantable cardioverter defibrillator; SCD = sudden cardiac death.
ESC Guidelines 7
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..A variety of terms are used that generally do not match the definitions
in this document closely enough to be used as synonyms of the defined
terms. For example, a ‘faint’ approximately conforms to syncope but
emphasizes vasovagal syncope (VVS) over other forms. A glossary of un-
certain terms is shown in section 1 of the Web Practical Instructions.
3.2 Classification and pathophysiology of
syncope and transient loss of
consciousness
3.2.1 Syncope
Table 3 provides a classification of the principal causes of syncope,
emphasizing groups of disorders with common pathophysiology,
presentation, and risk. Clinical features, epidemiology, prognosis, im-
pact on quality of life, and economic issues are shown in section 2 of
the Web Practical Instructions.
The pathophysiological classification centres on a fall in systemic
blood pressure (BP) with a decrease in global cerebral blood flow as
the defining characteristic of syncope. Figure 3 shows low BP and glo-
bal cerebral hypoperfusion as the central final common pathway of
syncope. A sudden cessation of cerebral blood flow for as short as
6–8 s can cause complete LOC. A systolic BP of 50–60 mmHg at
heart level, i.e. 30–45 mmHg at brain level in the upright position, will
cause LOC.8,9
Systemic BP is the product of cardiac output and total peripheral
resistance; a fall in either can cause syncope. However, in syncope,
both mechanisms often act together to a varying degree.
There are three primary causes of a low total peripheral resist-
ance. The first is decreased reflex activity causing vasodilatation
through withdrawal of sympathetic vasoconstriction: this is the
‘vasodepressive type’ of reflex syncope, seen in the outer ring in
Figure 3. The second is a functional impairment, and the third a struc-
tural impairment of the autonomic nervous system, with drug-
induced, primary, and secondary autonomic failure in the outer ring.
In autonomic failure, there is insufficient sympathetic vasoconstriction
in response to the upright position.
There are four primary causes of low cardiac output. The first is
a reflex bradycardia, known as cardioinhibitory reflex syncope.
The second concerns cardiovascular causes: arrhythmia, struc-
tural disease including pulmonary embolism, and pulmonary
hypertension. The third is inadequate venous return due to vol-
ume depletion or venous pooling. Finally, chronotropic and ino-
tropic incompetence through autonomic failure may impair
cardiac output.
Note that these primary mechanisms may interact in different
ways: firstly, venous pooling and inadequate venous return is also a
factor that can trigger an inappropriate reflex in orthostatic reflex
syncope; secondly, a low total peripheral resistance may cause ven-
ous pooling of blood below the diaphragm, in turn decreasing venous
return and consequently cardiac output.
The three main groups of syncope, i.e. reflex, cardiovascular, and
secondary to orthostatic hypertension (OH), are shown outside the
rings in Figure 3. Both reflex syncope and OH span the two main
pathophysiological mechanisms.
3.2.2 Non-syncopal forms of (real or apparent) transient
loss of consciousness
Only those forms of epilepsy in which normal motor control is lost,
so patients may fall, are included in Figure 2. These are tonic, clonic,
Generalized:
- Tonic
- Clonic
- Tonic-clonic
- Atonic
Psychogenic
  pseudosyncope (PPS)
Psychogenic non-epileptic
  seizures (PNES)
Figure 2 Syncope in the context of transient loss of consciousness. Non-traumatic transient loss of consciousness is classified into one of four
groupings: syncope, epileptic seizures, psychogenic transient loss of consciousness, and a miscellaneous group of rare causes. This order represents
their rate of occurrence. Combinations occur; e.g. non-traumatic transient loss of consciousness causes can cause falls with concussion, in which case
transient loss of consciousness is both traumatic and non-traumatic. TIA = transient ischaemic attack; TLOC = transient loss of consciousness.
8 ESC Guidelines
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Table 3 Classification of syncope
Reflex (neurally mediated) syncope
Vasovagal:
- orthostatic VVS: standing, less common sitting
- emotional: fear, pain (somatic or visceral), instrumentation, blood phobia
Situational:
- micturition
- gastrointestinal stimulation (swallow, defaecation)
- cough, sneeze
- post-exercise
- others (e.g. laughing, brass instrument playing)
Carotid sinus syndrome
Non-classical forms (without prodromes and/or without apparent triggers and/or atypical presentation)
Syncope due to OH
Note that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged
bed rest
(deconditioning).
Drug-induced OH (most common cause of OH):
- e.g. vasodilators, diuretics, phenothiazine, antidepressants
Volume depletion:
- haemorrhage, diarrhoea, vomiting, etc.
Primary autonomic failure (neurogenic OH):
- pure autonomic failure, multiple system atrophy, Parkinson’s disease, dementia with Lewy bodies
Secondary autonomic failure (neurogenic OH):
- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure
Cardiac syncope
Arrhythmia as primary cause:
Bradycardia:
- sinus node dysfunction (including bradycardia/tachycardia syndrome)
- atrioventricular conduction system disease
Tachycardia:
- supraventricular
- ventricular
Structural cardiac: aortic stenosis, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumours,
etc.), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valve dysfunction
Cardiopulmonary and great vessels: pulmonary embolus, acute aortic dissection, pulmonary hypertension
Remarks
• All forms of syncope, but mostly reflex syncope and OH, are more likely to occur or are more severe when various factors are present: medica-
tion causing low BP (due to vasodilatation or hypovolaemia), alcohol use, volume depletion (haemorrhage, low fluid intake, diarrhoea, vomiting),
pulmonary diseases causing reduction in brain oxygen supply, environmental factors (thermal stress).
• There are two main pathophysiological mechanisms in reflex syncope. “Vasodepression” refers to conditions in which insufficient sympathetic
vasoconstriction results in hypotension.1,2 “Cardioinhibition” is used when bradycardia or asystole predominates, reflecting a shift towards para-
sympathetic predominance. The haemodynamic pattern, i.e. cardioinhibitory, vasodepressive, or both, is independent of the trigger evoking reflex
syncope. For example, micturition syncope and orthostatic VVS may equally well present as cardioinhibitory or as vasodepressor syncope
• The non-classical form of reflex syncope involves a heterogeneous group of patients. The term is used to describe reflex syncope that occurs
with uncertain or apparently absent triggers and/or atypical presentation. The diagnosis of reflex syncope is probable when other causes of syn-
cope are excluded (absence of structural heart disease) and/or symptoms are reproduced in the tilt test.3 At present, this group also contains
syncope associated with low adenosine plasma levels4,5
• The cardiovascular causes of orthostatic intolerance include classical OH, initial OH, delayed OH, POTS, and VVS, which in this context can be
called orthostatic VVS.6,7 Syndromes of orthostatic intolerance that may cause syncope are presented in Web Practical Instruction section 2.
BP = blood pressure; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; VVS = vasovagal syncope.
ESC Guidelines 9
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
..
..
..
..
..
..
..
..
.
tonic-clonic, and atonic generalized seizures, and can be classified as
primary or secondary. The forms of epilepsy in which people remain
actively upright, i.e. sitting or standing (e.g. complex partial seizures
or absence epilepsy) are not regarded as TLOC, but sometimes they
are incorrectly diagnosed as syncope.
Psychogenic TLOC consists of two forms: one resembles epileptic
seizures (psychogenic non-epileptic seizures [PNES]) and one, with-
out gross movements, resembles syncope (psychogenic pseudosyn-
cope [PPS]).
The rare causes of TLOC only seldomly cause confusion with the
main TLOC forms, probably because in most cases they differ
enough clinically to be clearly not syncope. Both vertebrobasilar tran-
sient ischaemic attacks (TIAs) and subclavian steal syndrome are
associated with focal neurological signs. A subarachnoid haemor-
rhage may present with a short LOC, but the associated abrupt ex-
treme headache suggests the cause. In cyanotic breath-holding spells,
expiratory apnoea with hypoxia is the primary mechanism.10 So-
called ‘pallid breath-holding spells’ in children do not constitute a pri-
mary respiratory problem, but are cardioinhibitory reflex syncope.11
Table 4 lists the main features that distinguish syncope from dis-
orders that may be mistaken for syncope.
4. Diagnostic evaluation and
management according to risk
stratification
4.1 Initial evaluation
The clinical features characterizing TLOC are usually derived from his-
tory taking from patients and eyewitnesses. When a patient first presents
with possible TLOC, history taking should first establish whether there
was indeed a TLOC. Often, this allows a distinction between the major
TLOC groups. The flow diagram for the evaluation of TLOC is shown in
Figure 4. The initial evaluation should answer key questions:
(1) Was the event TLOC?
Figure 3 Pathophysiological basis of the classification of syncope.
ANS = autonomic nervous system; auton. = autonomic; BP =
blood pressure; OH = orthostatic hypotension; periph. =
peripheral; resist. = resistance.
Table 4 Conditions that may be incorrectly diagnosed
as syncope
Condition Characteristic features that distin-
guish from syncope
Generalized seizures See section 8, Table 10.
Complex partial seiz-
ures, absence epilepsy
No falls, yet unresponsive and later
amnesia
PPS or
“pseudocoma”
Duration of apparent LOC
lasting many minutes to hours; high
frequency, up to several times a day
Falls without TLOC No unresponsiveness or amnesia
Cataplexy Falls with flaccid paralysis and non-
responsive, yet no later amnesia
Intracerebral or sub-
arachnoid
haemorrhage
Consciousness may be progressively
reduced rather than immediately
lost. Accompanying severe head-
ache, other neurological signs
Vertebrobasilar TIA Always focal neurological signs and
symptoms, usually without LOC; if
consciousness is lost this usually lasts
longer than in TLOC.
Carotid TIA Consciousness is for all practical
purposes not lost in carotid TIAs,
but there are pronounced focal
neurological signs and symptoms
Subclavian steal
syndrome
Associated with focal neurological
signs
Metabolic disorders
including hypogly-
caemia, hypoxia,
hyperventilation with
hypocapnia
Duration much longer than in
TLOC; consciousness may be im-
paired instead of lost
Intoxication Duration much longer than in
TLOC; consciousness may be im-
paired instead of lost
Cardiac arrest LOC yet no spontaneous recovery
Coma Duration much longer than TLOC
LOC = loss of consciousness; PPS = psychogenic pseudosyncope; TIA = transient
ischaemic attack; TLOC = transient loss of consciousness.
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(2) In case of TLOC, is it of syncopal or non-syncopal origin?
(3) In case of suspected syncope, is there a clear aetiological diagnosis
(see section 4.1.1)?
(4) Is there evidence to suggest a high risk of cardiovascular events or
death (see section 4.1.2)?
TLOC has four specific characteristics: short duration, abnor-
mal motor control, loss of responsiveness, and amnesia for
the period of LOC (for an explanation of the clinical features of
TLOC see Web Table 4 in section 4.1 of the Web Practical
Instructions).
TLOC is probably syncope when: (i) there are signs and symptoms
specific for reflex syncope, syncope due to OH, or cardiac syncope,
and (ii) signs and symptoms specific for other forms of TLOC (head
trauma, epileptic seizures, psychogenic TLOC, and/or rare causes)
are absent. Practical instructions for history taking are given in sec-
tions 3 and 4 of the Web Practical Instructions.
When epileptic seizures or psychogenic attacks are likely, appro-
priate steps should be taken. By using a detailed clinical history, phys-
icians can differentiate syncope from other forms of TLOC in
approximately 60% of cases.12 For non-syncopal TLOC, refer to sec-
tions 7 and 8.
4.1.1 Diagnosis of syncope
The starting point of the diagnostic evaluation of TLOC of suspected
syncopal nature is the initial syncope evaluation, which consists of:
• Careful history taking concerning present and previous attacks, as
well as eyewitness accounts, in person or through a telephone
interview.
• Physical examination, including supine and standing BP
measurements.
• Electrocardiogram (ECG).
Based on these findings, additional examinations may be per-
formed when needed (see section 4.2):
• Immediate ECG monitoring when there is a suspicion of arrhyth-
mic syncope.
• Echocardiogram when there is previous known heart disease,
data suggestive of structural heart disease, or syncope secondary
to cardiovascular cause.
Figure 4 Flow diagram for the initial evaluation and risk stratification of patients with syncope. BP = blood pressure; ECG = electrocardiogram;
H&P exam = history and physical examination; TLOC = transient loss of consciousness.
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..• Carotid sinus massage (CSM) in patients aged >40 years.
• Head-up tilt testing when there is suspicion of syncope due to
OH or reflex syncope.
• Blood tests when clinically indicated, e.g. haematocrit or haemo-
globin when haemorrhage is suspected, oxygen saturation and
blood gas analysis when hypoxia is suspected, troponin when car-
diac ischaemia-related syncope is suspected, or D-dimer when
pulmonary embolism is suspected, etc.
Even if there is no independent gold/reference standard to diag-
nose syncope, there is strong consensus that the initial evalu-
ation may lead to certain or highly likely diagnosis when the
diagnostic criteria listed in the table of recommendations are
met.
Diagnostic criteria with initial evaluation
Recommendations Classa Levelb
Reflex syncope and OH
VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive prodrome
(pallor, sweating, and/or nausea).8,13–17
I C
Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers, listed in
Table 3.8,
13–17 I C
Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant significant OH.18–24 I C
In the absence of the above criteria, reflex syncope and OH should be considered likely when the features that suggest reflex
syncope or OH are present and the features that suggest cardiac syncope are absent (see Table 5).
IIa C
Cardiac syncope
Arrhythmic syncope is highly probable when the ECG shows25–39:
• Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in awake state and in absence of physical training;
• Mobitz II second- and third-degree AV block;
• Alternating left and right BBB;
• VT or rapid paroxysmal SVT;
• Non-sustained episodes of polymorphic VT and long or short QT interval; or
• Pacemaker or ICD malfunction with cardiac pauses.
I C
Cardiac ischaemia-related syncope is confirmed when syncope presents with evidence of acute myocardial ischaemia with or
without myocardial infarction.25–39
I C
Syncope due to structural cardiopulmonary disorders is highly probable when syncope presents in patients with prolapsing
atrial myxoma, left atrial ball thrombus, severe aortic stenosis, pulmonary embolus, or acute aortic dissection.
I C
Additional advice and clinical perspectives
The initial syncope evaluation, as described in this document, can define the cause of syncope in most patients. Strict adherence to the above defin-
itions of VVS and situational reflex syncope, and of syncope due to OH, can be considered certain or highly likely irrespective of the presence of
any other abnormal finding. In young subjects with unexplained syncope and no history of cardiac disease, no family history of sudden death, no su-
pine syncope or syncope during sleep or exercise, no unusual triggers, and a normal ECG, the chance of cardiac syncope is very low. SCD rates in
subjects <35 years amount to 1 – 3/100 000.
AV = atrioventricular; BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; OH = orthostatic hypo-
tension; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia; VVS = vasovagal syncope.
aClass of recommendation.
bLevel of evidence.
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When a diagnosis is nearly certain or highly likely, no further evalu-
ation is needed, and treatment—if any—can be planned. In other
cases, the initial evaluation may suggest a diagnosis when the features
listed in Table 5 are present, or otherwise is unable to suggest any
diagnosis.
4.1.2 Management of syncope in the emergency
department based on risk stratification
The management of TLOC of suspected syncopal nature in the ED
should answer the following three key questions:
(1) Is there a serious underlying cause that can be identified?
(2) What is the risk of a serious outcome?
(3) Should the patient be admitted to hospital?
Figure 5 shows a flow chart for the management and risk stratifica-
tion of patients referred to the ED for TLOC suspected to be syn-
cope (modified from Casagranda et al.40).
Question 1: Is there a serious underlying cause that can be
identified in the ED?
Normally the presenting complaint of syncope can be established.
The primary aim for an ED clinician is then to establish an underlying
diagnosis, especially those associated with the potential for rapid clin-
ical deterioration.41,42 It is the acute underlying disease that most fre-
quently determines short-term adverse events rather than the
syncope itself.43 Subsequent management will focus on treating this
underlying cause (Figure 5). Many (40–45%) non-cardiovascular and
some cardiovascular life-threatening underlying conditions are obvi-
ous in the ED.44 Table 6 lists high-risk features that suggest the pres-
ence of a serious underlying cause and low-risk features that suggest
a benign underlying cause.
Question 2:What is the risk of a serious outcome?
High-risk features are shown in Table 6, and how to use this risk pro-
file to guide subsequent management and disposition is shown in
Figure 6.
Risk stratification is important, for two reasons:
(1) To recognize patients with a likely low-risk condition able to be dis-
charged with adequate patient education.
(2) To recognize patients with a likely high-risk cardiovascular condition
requiring urgent investigation. This may require admission.
High-risk patients are more likely to have cardiac syncope.
Structural heart disease25–27,31,35,36,45 and primary electrical disease46
are major risk factors for sudden cardiac death (SCD) and overall
mortality in patients with syncope. Low-risk patients are more likely
to have reflex syncope and have an excellent prognosis.47 OH is
associated with a two-fold higher risk of death owing to the severity
of comorbidities compared with the general population.48
Question 3: Should the patient be admitted to hospital?
Approximately 50% of patients who present to the ED with
syncope are admitted (although the rate varies between 12–86%)
(see Supplementary Data Table 4). The use of clinical decision rules and
standardized protocols has not changed this rate significantly. The com-
posite estimate of outcomes is that in the next 7–30 days, only 0.8%
die and 6.9% have a non-fatal severe outcome whilst in the ED, while
another 3.6% have a post-ED serious outcome (see Supplementary
Data Table 4). Unnecessary admission in low-risk patients can be harm-
ful.87 Whereas it is crucial to identify these high-risk patients to ensure
early, rapid, and intensive investigation, not all patients at high risk need
hospitalization.80
Table 5 Clinical features that can suggest a diagnosis
on initial evaluation
Reflex syncope
• Long history of recurrent syncope, in particular occurring be-
fore the age of 40 years
• After unpleasant sight, sound, smell, or pain
• Prolonged standing
• During meal
• Being in crowded and/or hot places
• Autonomic activation before syncope: pallor, sweating, and/
or nausea/vomiting
• With head rotation or pressure on carotid sinus (as in tu-
mours, shaving, tight collars)
• Absence of heart disease
Syncope due to OH
• While or after standing
• Prolonged standing
• Standing after exertion
• Post-prandial hypotension
• Temporal relationship with start or changes of dosage of vas-
odepressive drugs or diuretics leading to hypotension
• Presence of autonomic neuropathy or parkinsonism
Cardiac syncope
• During exertion or when supine
• Sudden onset palpitation immediately followed by syncope
• Family history of unexplained sudden death at young age
• Presence of structural heart disease or coronary artery
disease
• ECG findings suggesting arrhythmic syncope:
- Bifascicular block (defined as either left or right BBB com-
bined with left anterior or left posterior fascicular block)
- Other intraventricular conduction abnormalities (QRS dur-
ation >_0.12 s)
- Mobitz I second-degree AV block and 1 degree AV block
with markedly prolonged PR interval
- Asymptomatic mild inappropriate sinus bradycardia (40–50
b.p.m.) or slow atrial fibrillation (40–50 b.p.m.) in the ab-
sence of negatively chronotropic medications
- Non-sustained VT
- Pre-excited QRS complexes
- Long or short QT intervals
- Early repolarization
- ST-segment elevation with type 1 morphology in leads
V1-V3 (Brugada pattern)
- Negative T waves in right precordial leads, epsilon waves
suggestive of ARVC
- Left ventricular hypertrophy suggesting hypertrophic
cardiomyopathy
ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular;
BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardio-
gram; OH = orthostatic hypotension; VT = ventricular tachycardia.
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Figure 5 The management of patients presenting to the emergency department for transient loss of consciousness suspected to be syncope
(modified from Casagranda et al.40). ED = emergency department; TLOC = transient loss of consciousness.
aFor example, this includes pulmonary embolism presenting with shortness of breath, pleuritic chest pain, and syncope, but not trauma
secondary to syncope.
Management of syncope in the emergency department
Recommendations Classa Levelb
It is recommended that patients with low-risk features, likely to have reflex or situational syncope, or syncope due to OH,
are discharged from the ED.27,35,36,49–54,58,62,69
I B
It is recommended that patients with high-risk features receive an early intensive and prompt evaluation in a syncope unit or
in an ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76
I B
It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit
instead of being hospitalized.40,63–65,77
I B
Risk stratification scores may be considered for risk stratification in the ED.78–86 IIb B
Additional advice and clinical perspectives
• In the ED, presyncope should be managed with the same accuracy as syncope as it carries the same prognosis.66–68
• Diagnostic radiology and laboratory tests such as chest X-ray, brain computed tomography, routine blood haematology, biochemistry, and D-dimer and cardiac
markers have a low diagnostic yield, impact on risk stratification of patients with syncope, and should not routinely be used unless specifically suggested by clinical
evaluation.
• Around 10% of patients with syncope in the ED will suffer from a serious outcome within 7–30 days of their visit, with just under half occurring after their stay in the
ED (see Supplementary Data Table 4). It is crucial to identify these high-risk patients to ensure early, rapid, and intensive investigation.
• As syncope units are both effective and efficient, this early, rapid, and intensive investigation can be performed on an outpatient basis (either in a syncope unit or an
ED observation unit) in most cases. Only patients with a risk of a short-term serious outcome should be considered for hospital admission.
• To reduce inappropriate admissions, patients who have a cardiac device and syncope should undergo prompt device interrogation.
• Risk stratification scores perform no better than good clinical judgement and should not be used alone to perform risk stratification in the ED.
ED = emergency department; OH = orthostatic hypotension.
aClass of recommendation.
bLevel of evidence.
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Table 6 High-risk features (that suggest a serious condition) and low-risk features (that suggest a benign condition) in
patients with syncope at initial evaluation in the emergency department
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AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; BP = blood pressure; b.p.m. = beats per minute; ECG = electrocardio-
gram; ED = emergency department; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; SCD = sudden cardiac
death; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
aSome ECG criteria are per se diagnostic of the cause of the syncope (see recommendations: Diagnostic criteria); in such circumstances appropriate therapy is indicated without
further investigations. We strongly suggest the use of standardized criteria to identify ECG abnormalities with the aim of precise diagnosis of ECG-defined cardiac syndromes in
ED practice.61
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..The diagnostic tests, procedures, and interventions that may re-
quire admission in patients with high-risk features are listed in Table 7.
Furthermore, this Task Force believes that the implementation
of novel care pathways and organizational approaches, such as ED ob-
servation units and syncope in- and outpatient units (Figure 6),
offer safe and effective alternatives to admission in the cases
listed in Table 7. Based on a consensus document,40 a single-centre
experience consisting of a short stay in the ED under observation of
<_48 h coupled with fast-tracking to a syncope unit reduced the ad-
mission rate to 29%.77 Among patients not admitted, 20% were dis-
charged after a short observation in the ED, 20% were fast-tracked to
the syncope unit, and 31% were discharged directly from the ED.77
Risk stratification scores: There are several ED syncope clinical
decision rules that aim to stratify patients with syncope based on
medical history, examination, and ECG findings (see Supplementary
if
Figure 6 Emergency department risk stratification flow chart. Low- and high-risk features are listed in Table 6. ED = emergency department;
SU = syncope unit.
Patients with low-risk features. These patients do not need further diagnostic tests in the ED as they are likely to have reflex, situational,
or orthostatic syncope. They may benefit from reassurance, or counselling (see Web Practical Instructions section 9.1: ESC information
sheet for patients affected by reflex syncope).
Patients with high-risk features. These patients should be classified as HIGH RISK; they require an intensive diagnostic approach and may
need urgent treatment and admission. These patients should be monitored (although it is unclear for how long this should be, most
studies suggesting up to 6 hours in the ED and up to 24 hours in hospital) in a setting where resuscitation can be performed in case of
deterioration.40,62
Patients that have neither high- nor low-risk features. These patients will require expert syncope opinion, which can probably be safely man-
aged in an outpatient setting.63 There is no direct evidence that admitting patients to hospital changes their outcome, whilst there is evi-
dence that management in an ED observation unit and/or fast-track to a syncope outpatient unit is beneficial.64,65
aRecent studies have suggested that outcomes in patients presenting with presyncope are similar to those presenting with
syncope.66–68
bThese patients may still require admission to hospital for associated illness, injury or welfare reasons. Low-risk patients can be referred
to the outpatient syncope clinic for therapy purposes, if needed.
ESC Guidelines 17
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..Data Table 3).26,34–36,44,88 None of these rules are used widely in EDs
due to poor sensitivity and specificity reported from external valida-
tion, or due to a lack of external validation.70,78–85 Syncope clinical
decision rules perform no better than clinician judgment at predicting
short-term serious outcomes.86 Clinical decision rules can predict
poor outcomes, but most syncope deaths and many poor outcomes
are associated with underlying illness rather than syncope per se,58
particularly in the long term.56
Even if the quality of evidence is moderate, there is strong con-
sensus from several studies that currently available risk stratifi-
cation scores have not shown better sensitivity, specificity, or
prognostic yield compared with clinical judgment in predicting
short-term serious outcomes after syncope. Therefore, they
should not be used alone to perform risk stratification in
the ED.
4.2 Diagnostic tests
4.2.1 Carotid sinus massage
A ventricular pause lasting >3 s and/or a fall in systolic BP of >50
mmHg is known as carotid sinus hypersensitivity. Carotid sinus
hypersensitivity is a common finding in older men without syn-
cope; abnormal responses are frequently observed (<_40%) in
patients without syncope, especially if they are older and affected
by cardiovascular disease.89 Carotid sinus hypersensitivity is
exceptional in patients <40 years of age.90 The specificity of the
test increases if spontaneous syncope is reproduced during CSM.
Syncope was induced in only 5% of asymptomatic persons aged
>65 years.89 For the above reasons, the diagnosis of carotid sinus
syndrome (CSS) requires the reproduction of spontaneous symp-
toms and, in addition, that patients have syncope of unknown ori-
gin compatible with a reflex mechanism. In such circumstances,
CSM usually shows a period of asystole >6 s.91 The prevalence of
CSS, as defined here, was 8.8% when CSM was performed after
the initial evaluation in 1855 consecutive patients >40 years of
age with syncope compatible with a reflex mechanism.92,93 In a
multicentre study94 aimed at validation of the 2009 ESC
Guidelines, CSM was indicated after initial evaluation in 73% of
700 patients and was diagnostic in 12%. The precise methodology
and results of CSM are shown in section 5 of the Web Practical
Instructions.
The main complications of CSM are neurological. When pooling
the data from four studies90,95–97 in which 8720 patients were ana-
lysed, TIAs or strokes were observed in 21 (0.24%).
The relationship between abnormal response to CSM and
spontaneous syncope is a crucial point that has been studied using
two methods. The first was a pre-post comparison of the recur-
rence rate of syncope after pacing. Non-randomized studies dem-
onstrated fewer recurrences at follow-up in paced patients than in
those without pacing. These results were confirmed in two
randomized trials.98,99 The second method was to analyse the
occurrence of asystolic episodes registered in patients with a car-
dioinhibitory response to CSM using an implanted device.
Recordings of long pauses were very common in the two trials
that employed this method.100,101 These results suggest that a
positive response to CSM, reproducing symptoms, in patients
with syncope is highly predictive of the occurrence of spontane-
ous asystolic episodes.
Table 7 High-risk syncope patients: criteria favouring a stay in an emergency department observation unit and/or
fast-tracking to a syncope unit vs. requiring admission to hospital
Favour initial management in ED observation unit and/or
fast-track to syncope unit
Favour admission to hospital
High-risk features AND:
• Stable, known structural heart disease
• Severe chronic disease
• Syncope during exertion
• Syncope while supine or sitting
• Syncope without prodrome
• Palpitations at the time of syncope
• Inadequate sinus bradycardia or sinoatrial block
• Suspected device malfunction or inappropriate intervention
• Pre-excited QRS complex
• SVT or paroxysmal atrial fibrillation
• ECG suggesting an inheritable arrhythmogenic disorders
• ECG suggesting ARVC
High-risk features AND:
• Any potentially severe coexisting disease that requires admission
• Injury caused by syncope
• Need of further urgent evaluation and treatment if it cannot
be achieved in another way (i.e. observation unit), e.g. ECG monitoring,
echocardiography, stress test, electrophysiological study, angiography,
device malfunction, etc.
• Need for treatment of syncope
ARVC = arrhythmogenic right ventricular cardiomyopathy; ECG = electrocardiogram; ED = emergency department; SVT = supraventricular tachycardia.
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There is strong consensus that the diagnosis of CSS requires
both the reproduction of spontaneous symptoms during CSM
and clinical features of spontaneous syncope compatible with
a reflex mechanism. The quality of evidence is moderate and is
given by studies of ECG correlation between CSM and sponta-
neous events, and indirectly by studies of efficacy of cardiac
pacing. Further research is likely to have an important impact
on our confidence in the estimation of effect and may change
the estimate.
4.2.2 Orthostatic challenge
Changing from the supine to the upright position produces a dis-
placement of blood from the thorax to the lower limbs and abdomi-
nal cavity that leads to a decrease in venous return and cardiac
output. In the absence of compensatory mechanisms, a fall in BP may
lead to syncope.20,103,104 The diagnostic criteria for OH have been
defined by consensus.6
Currently, there are three methods for assessing the response to
change in posture from supine to erect20,103,104: active standing (see
section 4.2.2.1), head-up tilt (see section 4.2.2.2), and 24-h ambula-
tory BP monitoring (ABPM) (see section 4.2.3.4).
4.2.2.1 Active standing
Indications: This test is used to diagnose different types of ortho-
static intolerance (see Web Practical Instructions Web Table 1). A
sphygmomanometer is adequate for routine clinical testing for classi-
cal OH and delayed OH because of its ubiquity and simplicity.
Automatic arm-cuff devices, which are programmed to repeat and
confirm measurements when discrepant values are recorded, are at
a disadvantage due to the rapidly falling BP during OH. With a sphyg-
momanometer, more than four measurements per minute cannot
be obtained without venous obstruction in the arm. When more fre-
quent readings are required, as for initial OH, continuous beat-to-
beat non-invasive BP measurement is needed.20,103,104
Diagnostic criteria: Abnormal BP fall is defined as a progressive
and sustained fall in systolic BP from baseline value >_20 mmHg or
diastolic BP >_10 mmHg, or a decrease in systolic BP to <90
mmHg. This definition of OH differs from the 2011 consensus6 in
adding the 90 mmHg threshold. This Task Force believes that an
absolute threshold of 90 mmHg of systolic BP is useful, especially
in patients with a supine BP <110 mmHg. An isolated diastolic BP
drop is very rare and its clinical relevance for OH diagnosis is lim-
ited. Orthostatic heart rate (HR) increase is blunted or absent
[usually not >10 beats per minute (b.p.m.)] in patients with neuro-
genic OH, but increases or even exaggerates with anaemia or
hypovolaemia. The probability that syncope and orthostatic com-
plaints are due to OH can be assessed using the information given
in Table 8.
Cardiac sinus massage
Recommendations Classa Levelb
Indications
CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 I B
Diagnostic criteria
CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduce spontaneous symptoms, and
patients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102
I B
Additional advice and clinical perspectives
• History of syncope and its reproduction by CSM defines CSS; positive CSM without a history of syncope defines carotid sinus hypersensitiv-
ity.89,90,92,93 Carotid sinus hypersensitivity in patients with unexplained syncope may be a non-specific finding because it is present in <_40% of
older populations and should be used with caution for diagnosis of the mechanism of syncope.
• CSM should be performed with the patient in the supine and upright positions, and with continuous beat-to-beat BP monitoring. This may be
more readily performed in the tilt laboratory.90
• Although neurological complications are very rare,90,95–97 the risk of provocation of TIA with the massage suggests that CSM should be under-
taken with caution in patients with previous TIA, stroke, or known carotid stenosis >70%.
BP = blood pressure; CSM = carotid sinus massage; CSS = carotid sinus syndrome; TIA = transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
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Active standing
Recommendations Classa Levelb
Indications
Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-
cated at initial syncope evaluation.20,103,104
I C
Continuous beat-to-beat non-invasive BP and HR measurement may be preferred when short-lived BP variations are sus-
pected, such as in initial OH.20,103,104
IIb C
Diagnostic criteria
Syncope due to OH is confirmed when there is a fall in systolic BP from baseline value >_20 mmHg or diastolic BP >_10
mmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104
I C
Syncope due to OH should be considered likely when there is an asymptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are consistent
with OH.6,20,103,104
IIa C
Syncope due to OH should be considered likely when there is a symptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and not all of the features (from history) are
suggestive of OH.6,20,103,104
IIa C
POTS should be considered likely when there is an orthostatic HR increase (>30 b.p.m. or to >120 b.p.m. within 10 min of
active standing) in the absence of OH that reproduces spontaneous symptoms.6,20,103,104
IIa C
Syncope due to OH may be considered possible when there is an asymptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are less consis-
tent with OH.6,20,103,104
IIb C
BP = blood pressure; b.p.m. = beats per min; OH = orthostatic hypotension; HR = heart rate; POTS = postural orthostatic tachycardia syndrome.
aClass of recommendation.
bLevel of evidence.
Table 8 Association of orthostatic intolerance and orthostatic hypotension
History of syncope and orthostatic complaints
Highly suggestive of OH: syncope and pre-
syncope are present during standing, absent
while lying, and less severe or absent while sit-
ting; a predilection for the morning; sitting or
lying down must help; complaints may get
worse immediately after exercise, after meals
or in high temperatures; no “autonomic
activation”
Possibly due to OH: not all of the features
highly suggestive of OH are present
Supine and standing
BP measurement
Symptomatic abnormal BP fall Syncope is due to OH (Class I) Syncope is likely due to OH (Class IIa)
Asymptomatic abnormal BP fall Syncope is likely due to OH (Class IIa) Syncope may be due to OH (Class IIb)
No abnormal BP drop Unproven Unproven
BP = blood pressure; OH = orthostatic hypotension.
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..4.2.2.2 Tilt testing
Since its introduction in 1986,105 many protocols have been reported
with variations in the initial stabilization phase, duration, tilt angle,
type of support, and pharmacological provocation. The most com-
monly used are the trinitroglycerin (TNG) test using 300–400 mg of
sublingual TNG after a 20-min unmedicated phase,106,107 and the
low-dose intravenous isoproterenol test, which uses incremental
doses to increase average HR by about 20–25% over baseline (usu-
ally <_3 mg/min).108,109 In a recent systematic literature review,110 the
overall positivity rate in patients with syncope was 66% for the TNG
protocol and 61% for the isoproterenol protocol; the respective pos-
itivity rate in subjects without syncope (controls) ranged from
11–14%; and the test differentiated patients with syncope from con-
trols with an odds ratio of 12. The methodology and classification of
responses are described in section 6 of the Web Practical Instructions.
Adding video recording to a tilt table permits objective and repeated
review of clinical signs in relation to BP and HR, and helps to assess
the relative contribution of bradycardia and hypotension to syncope
(see section 5.2.6.3 and the explanatory video in Web Practical
Instructions section 6.3.15), and to distinguish between VVS and PPS
(see section 4.2.5).
The clinical situation corresponding to tilt-induced syncope is that
which is triggered by prolonged standing. The test should be
considered: (i) to confirm a diagnosis of reflex syncope in patients in
whom this diagnosis was suspected but not confirmed by initial eval-
uation105–109,111, and (ii) for the assessment of autonomic
failure, especially for the reproduction of delayed OH (which could not
be detected by active standing because of its delayed onset)23,24,112,113
and postural orthostatic tachycardia syndrome (POTS).114 Tilt testing
may be helpful in separating syncope from PPS.115–117
Tilt testing has limited value in assessing treatment efficacy.118
However, tilt testing is widely accepted as a useful tool to demon-
strate susceptibility of the patient to reflex syncope, especially a
hypotensive (vasodepressive) tendency, and thereby to initiate treat-
ment (e.g. physical manoeuvres, see section 5).119–121
The endpoint of tilt testing is the reproduction of
symptoms along with the characteristic circulatory pattern of
the indication mentioned above, namely the induction of reflex hypo-
tension/bradycardia, OH, POTS, or PPS. The typical tilt test result
patterns are shown in the Web Practical Instructions section 6.
Interpretation of tilt testing results in patients with reflex syncope:
Some studies122,123 compared the response to tilt testing with sponta-
neous syncope recorded by an implantable loop recorder (ILR). While
a positive cardioinhibitory response to tilt testing predicts, with a high
probability, an asystolic spontaneous syncope, the presence of a
Tilt testing
Recommendations Classa Levelb
Indications
Tilt testing should be considered in patients with suspected reflex syncope, OH, POTS, or PPS.23,24,105–109,111–117 IIa B
Tilt testing may be considered to educate patients to recognize symptoms and learn physical manoeuvres.119–121 IIb B
Diagnostic criteria
Reflex syncope, OH, POTS, or PPS should be considered likely if tilt testing reproduces symptoms along with the charac-
teristic circulatory pattern of these conditions.23,24,105–109,111–117
IIa B
Additional advice and clinical perspectives
• A negative tilt table response does not exclude a diagnosis of reflex syncope.
• While sensitivity and specificity are at acceptable levels when measured in patients with VVS and healthy controls, in usual clinical settings of syncope
of uncertain origin tilt testing suggests the presence of a hypotensive susceptibility, which may exist not only in reflex syncope but also with other
causes of syncope including some forms of cardiac syncope. The concept of hypotensive susceptibility rather than diagnosis has important practical
utility, because the presence or absence of hypotensive susceptibility plays a major role in guiding pacemaker therapy in patients affected by reflex
syncope and in the management of hypotensive therapies, which are frequently present in the elderly with syncope (see sections 5.1 and 5.2).
• A positive cardioinhibitory response to tilt testing predicts, with high probability, asystolic spontaneous syncope; this finding is relevant for thera-
peutic implications when cardiac pacing is considered (see section 5.2.6). Conversely, the presence of a positive vasodepressor, a mixed
response, or even a negative response does not exclude the presence of asystole during spontaneous syncope.122,123
• Tilt testing may be helpful in separating syncope with abnormal movements from epilepsy.137
• Tilt testing may have value in distinguishing syncope from falls.23
• Tilt testing may be helpful in separating syncope from PPS. In suspected PPS, the tilt test should preferably be performed together with EEG mon-
itoring; a normal EEG helps to confirm the diagnosis.116,117 In the absence of an EEG, a video recording will be helpful in confirming the diagnosis.
• Tilt testing should not be used to assess the efficacy of a drug treatment.118
EEG = electroencephalogram; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; PPS = psychogenic pseudosyncope; VVS = vasovagal
syncope.
aClass of recommendation.
bLevel of evidence.
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positive vasodepressor, mixed response, or even a negative response,
does not exclude the presence of asystole during spontaneous
syncope.122,123
Tilt testing has an acceptable sensitivity124 and specific-
ity106,124,125 when these are calculated in patients with true VVS
or without a history of syncope. However, there is an inability to
apply the test to populations with syncope of uncertain cause
where it is hoped that tilt testing might prove decisive. In these
clinical settings, tilt testing fails to deliver (Figure 7). Indeed, tilt
testing was positive in 51–56% of patients with atypical clinical fea-
tures suggesting a reflex mechanism,106,124–128 in 30–36% with
unexplained syncope after full investigation,124,129 and in 45–47%
with true cardiac arrhythmic syncope.130,131 In other words, tilt
testing offers little diagnostic value in patients for whom it is most
needed. In these patients, a positive tilt test reveals a susceptibility
to orthostatic stress.132 This hypotensive susceptibility plays a role in
causing syncope irrespective of the aetiology and mechanism of
syncope. For example, in arrhythmic syncope caused by paroxys-
mal atrial tachyarrhythmias, the mechanism is a combination of
onset of the arrhythmia itself and hypotensive susceptibility,
corroborated by positive tilt testing.130,131 Similarly, multifactorial
mechanisms are likely in other types of cardiac syncope, e.g. aortic
stenosis,133 hypertrophic cardiomyopathy (HCM),134 and
sick sinus syndrome.135,136 The presence or absence of suscepti-
bility explains the occurrence of syncope in some and not in
others affected by the same severity of arrhythmia or structural
defect. Tilt testing should now be considered a means of
exposing a hypotensive tendency rather than being diagnostic of
VVS. This concept has practical implications for therapy (see sec-
tions 5.1 and 5.2).
4.2.3 Basic autonomic function tests
Autonomic function assessment helps to identify autonomic failure as
the underlying cause of syncope.
4.2.3.1 Valsalva manoeuvre
The methodology of the Valsalva manoeuvre is described in section
7.1.1 of the Web Practical Instructions and in Web Video 2. There is
strong evidence that the absence of a BP overshoot and an absence
of a HR increase during the Valsalva is pathognomonic for neurogenic
OH, occurring in primary and secondary autonomic failure, and the
degree of hypotension and/or lack of compensation during forced
expiration usually correlate with the degree of autonomic dysfunc-
tion and related symptoms.138–143 In contrast, a pronounced BP fall
beyond what is normally expected during forced expiration, but a
normal chronotropic response during the manoeuvre, may occur in
patients with suspected situational syncope, i.e. syncope occurring
during some forms of situational syncope, e.g. coughing, brass instru-
ment playing, singing, and weightlifting.144
4.2.3.2 Deep breathing
The methodology of the deep-breathing test is described in section
7.1.2 of the Web Practical Instructions. Under physiological conditions,
HR rises during inspiration and falls during expiration. HR variability
during deep breathing (also called the expiratory/inspiratory index or
E/I index) is >_15 b.p.m. in healthy individuals aged >50 years.145
There is strong consensus that blunted or abolished variation is sug-
gestive of parasympathetic dysfunction.142,143,146,147
4.2.3.3 Other autonomic function tests
Further tests to evaluate cardiovascular sympathetic function include
calculation of the 30:15 ratio, the cold pressure test, the sustained
hand grip test, and mental arithmetic. There is weak evidence that
these tests may be useful.13,142,143,147
4.2.3.4 Twenty-four-hour ambulatory and home blood pressure
monitoring
Twenty-four-hour ABPM and home BP monitoring (HBPM) are
increasingly used to diagnose and monitor the treatment of hyperten-
sion.148 There is strong evidence that OH is frequently associated with
a nocturnal ‘non-dipping’ or even ‘reverse-dipping’ BP pattern in
patients with autonomic failure, with relevant therapeutic and prognos-
tic implications140,148–151 (see Web Practical Instructions section 7.1.3). In
these patients, ABPM allows the assessment of nocturnal hypertension,
postprandial hypotension, and exercise- and drug-induced hypoten-
sion, as well as monitoring for side effects of antihypotensive regimens
and pointing to additional disorders such as sleep apnoea.152 There is
weak evidence that ABPM may also detect the degree of OH in daily
life better than single office BP measurements.153
HBPM may be used to investigate the cause of orthostatic intoler-
ance, i.e. to clarify whether symptoms are due to OH or to other
causes, such as vertigo or motor imbalance in Parkinson’s disease or
multiple system atrophy. The evidence is weak. Finally, HBPM can be
used to clarify that BP is not low during episodes of PPS.154
Figure 7 Rates of tilt testing positivity in different clinical condi-
tions. These studies used the Westminster protocol for passive
tilt,125 the Italian protocol for trinitroglycerin tilt,106 and the clo-
mipramine protocol,124 for a total of 1453 syncope patients and
407 controls without syncope. Studies using other tilt protocols,
e.g. isoproterenol challenge, were not included. Clom = clomipr-
amine; TNG = trinitroglycerin; VVS = vasovagal syncope.
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..4.2.4 Electrocardiographic monitoring (non-invasive and
invasive)
The role of ECG monitoring cannot be defined in isolation. As a rule,
ECG monitoring is indicated only when there is a high pre-test proba-
bility of identifying an arrhythmia associated with syncope, such as
those listed in Table 5.
4.2.4.1 In-hospital monitoring
In-hospital monitoring (in bed or by telemetry) is warranted in
patients with high-risk clinical features (defined in Table 6) suggesting
arrhythmic syncope, especially if the monitoring is applied immedi-
ately after syncope. Although the diagnostic yield of ECG monitoring
varies from 1.9–17.6%,158–160 it is justified by the need to avoid
immediate risk to the patient.
4.2.4.2 Holter monitoring
Since, in most patients, symptoms do not recur during monitoring, the
true yield of Holter monitoring in syncope may be as low as 1–2% in
an unselected population. In 15% of patients, symptoms were not asso-
ciated with arrhythmia.161 Thus, in these patients, a rhythm disturbance
could potentially be excluded as a cause of syncope. Holter monitoring
in syncope is inexpensive in terms of set-up costs, but expensive in
terms of cost per diagnosis.162 Holter monitoring in syncope may be of
more value if symptoms are frequent. Daily single or multiple episodes
of LOC might increase the potential for symptom–ECG correlation.
4.2.4.3 Prospective external event recorders
Event recorders are external devices that are applied by the patient
when symptoms occur. Whereas these recorders can be useful in
Basic autonomic function tests
Recommendations Classa Levelb
Valsalva manoeuvre
Valsalva manoeuvre should be considered for the assessment of autonomic function in patients with suspected neurogenic
OH.138–143
IIa B
Valsalva manoeuvre may be considered for confirming the hypotensive tendency induced by some forms of situational syn-
cope, e.g. coughing, brass instrument playing, singing, and weightlifting.144
IIb C
Deep-breathing test
Deep-breathing tests should be considered for the assessment of autonomic function in patients with suspected neurogenic
OH.142,143,146,147
IIa B
Other autonomic function tests
Other autonomic function tests (30:15 ratio, cold pressure test, sustained hand grip test, and mental arithmetic test) may
be considered for the assessment of autonomic function in patients with suspected neurogenic OH.13,142,143,147
IIb C
ABPM
ABPM is recommended to detect nocturnal hypertension in patients with autonomic failure.140,148–151 I B
ABPM should be considered to detect and monitor the degree of OH and supine hypertension in daily life in patients with
autonomic failure.152,153
IIa C
ABPM and HBPM may be considered to detect whether BP is abnormally low during episodes suggestive of orthostatic
intolerance.
IIb C
Additional advice and clinical perspectives
• Whenever possible, reproduction of the trigger situation (e.g. coughing, swallowing, laughing, bass instrument playing, weightlifting) under beat-
to-beat non-invasive HR and BP measurement should be performed in patients with suspected situational syncope.
• The effects of age and sex should be considered when interpreting autonomic function tests.145,155–157
• Compliance with autonomic function tests may be limited in patients with dementia. Patients with tremor or Parkinsonism may not succeed in
performing the sustained hand grip test. The cold pressure test may be uncomfortable in patients with Raynaud’s phenomena.147
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring; HR = heart rate; OH = orthostatic hypotension.
aClass of recommendation.
bLevel of evidence.
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..the investigation of palpitations,163 they have a marginal role in the
evaluation of syncope.
4.2.4.4 Smartphone applications
Because up to now smartphone applications have recorded real-time
ECG, their current role in syncope is limited for the same reason as
for prospective event recorders.164,165 However, home video
records are very useful in all forms of TLOC (see section 4.2.5.2).
4.2.4.5 External loop recorders
In general, external loop recorders have a higher diagnostic yield than
Holter monitoring.162 External loop recorders can be useful in
patients with relatively frequent syncope episodes.166–168 In a recent
multicentre international registry, the diagnostic yield in syncope was
24.5%, with the most common finding being bradyarrhythmias; the
stronger predictor for diagnostic findings was early monitoring after
the index event.166
4.2.4.6 Remote (at home) telemetry
Most recently, external and implantable device systems have been
developed that provide continuous ECG recording or 24-h loop
memory with wireless transmission (real time) to a service centre.
Some recent studies have shown that implementing remote monitor-
ing increases the diagnostic yield and achieves diagnosis earlier than
without remote monitoring.169–171
4.2.4.7 Implantable loop recorders
In a meta-analysis of five randomized controlled trials (RCTs),172–176
660 patients with unexplained syncope were randomized to a con-
ventional strategy consisting of an external loop recorder, tilt testing,
and an electrophysiological study (EPS), or to prolonged monitoring
with an ILR. The results showed that initial implantation of an ILR in
the workup provided a 3.7 [95% confidence interval (CI) 2.7–5.0]
increased relative probability of a diagnosis compared with the con-
ventional strategy (see Supplementary Data Table 5). ILR was more
cost-effective than a conventional strategy.172,173,177,178
In pooled data from nine studies179 performed in 506 patients with
unexplained syncope at the end of complete negative work-up, a cor-
relation between syncope and ECG was found in 176 patients (35%);
of these, 56% had asystole (or bradycardia in a few cases) at the time
of the recorded event, 11% had tachycardia, and 33% had no arrhyth-
mia. Presyncope was much less likely to be associated with an
arrhythmia than syncope. Similar findings were subsequently
observed with ILR use expanded in an early phase of evaluation in
patients with recurrent syncope of uncertain origin, in the absence of
high-risk criteria and structural heart disease,176,180–183 and in sus-
pected reflex syncope.184–186 In particular, an asystolic pause was
present during syncope in about 50% of these patients.
There are several areas of interest other than unexplained syn-
cope in which ILRs have been investigated:
• Patients with bundle branch block (BBB) in whom paroxysmal
atrioventricular (AV) block is likely despite negative complete
EPS: an arrhythmia was observed in 41% of these patients (being
paroxysmal AV block in 70%) under ILR observation, based on
pooled data from three studies174,187,188 (see Supplementary Data
Table 6).
• Patients in whom epilepsy was suspected but the treatment has
proven ineffective: in pooled data, an attack could have
been documented by ILR in 62% of patients, with an arrhythmic
cause being responsible in 26%137,189–191 (see Supplementary Data
Table 7).
• Patients with unexplained falls: in pooled data, an attack could
have been documented by ILR in 70% of patients, with an
arrhythmic cause being responsible in 14%191–194 (see
Supplementary Data Table 8).
• Patients with HCM, arrhythmogenic right ventricular cardiomy-
opathy (ARVC), or primary electrical diseases (see section 5.4).
4.2.4.8 Diagnostic criteria
The gold standard for the diagnosis of arrhythmic syncope is when
there is a correlation between the symptoms and an ECG record-
ing.195,196 The presence of asymptomatic significant arrhythmias—
defined as prolonged asystole (>_3 s), rapid supraventricular
tachycardias (SVTs) (i.e. >160 b.p.m. for >32 beats), or ventricular
tachycardias (VTs)—has been considered by several authors to be a
diagnostic finding.185,188,197–199 On the other hand, although the
absence of documentation of an arrhythmia during a syncopal epi-
sode cannot be considered to be a specific diagnosis, it allows the
exclusion of an arrhythmia as the mechanism of the syncope. Most
evidence in support of the above diagnostic criteria is indirectly based
on the benefit of specific therapies guided by ECG monitoring in pre-
venting syncopal recurrences.172,184–186,188,200
Even if the quality of evidence is moderate, there is strong con-
sensus based on evidence from several controlled trials that a
correlation between symptoms and a documented arrhythmia,
or the presence of some asymptomatic significant arrhythmias
(defined above), is diagnostic of the cause of syncope and spe-
cific treatmentmust be prescribed.
The principal limitation of any ECG monitoring device is the
inability to record BP together with ECG. In reflex syncope, the
documentation of bradycardia/asystole during a syncopal episode
does not rule out the possibility that a hidden hypotensive reflex
is the principal cause for syncope, and that bradycardia/asystole is
a secondary late event. This issue has important implications for
therapy (see section 5). A classification of ECG recordings with
their probable related pathophysiology is available in Web Table 6
and Web Practical Instructions section 8.
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..4.2.5 Video recording in suspected syncope
4.2.5.1 In-hospital video recording
For PNES, a video-electroencephalogram (EEG) forms the highest
level of diagnostic probability.204 For syncope and PPS, video can play
a similar, probably underused, role (see section 7). Adding video
recording to a tilt table test adds the ability to review clinical signs in
relation to BP and HR objectively and repeatedly, thus helping to dis-
tinguish VVS from PPS. This approach has revealed new pathophysio-
logical insights in syncope.9 Attaching the camera to the tilt table
allows detailed study of the face and head, which is useful when
assessing the start and end of LOC.9,205 Video recording of tilt-
induced PPS116 ensures that apparent TLOC occurs while BP and HR
Electrocardiographic monitoring
Recommendations Classa Levelb
Indications
Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). I C
Holter monitoring should be considered in patients who have frequent syncope or presyncope (>_1 episode per week).161 IIa B
External loop recorders should be considered, early after the index event, in patients who have an inter-symptom interval <_4
weeks.162,166,168,201
IIa B
ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk
criteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202,
Supplementary Data Table 5
I A
ILR is indicated in patients with high-risk criteria (listed in Table 6) in whom a comprehensive evaluation did not demon-
strate a cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary preven-
tion ICD or pacemaker indication.174,180,187,188,195, Supplementary Data Tables 5 and 6
I A
ILR should be considered in patients with suspected or certain reflex syncope presenting with frequent or severe syncopal
episodes.184–186
IIa B
ILR may be considered in patients in whom epilepsy was suspected but the treatment has proven ineffective.137,189–191,
Supplementary Data Table 7
IIb B
ILR may be considered in patients with unexplained falls.191–194, Supplementary Data Table 8 IIb B
Diagnostic criteria
Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-
rhythmia) is detected.172,184–186,188,200
I B
In the absence of syncope, arrhythmic syncope should be considered likely when periods of Mobitz II second- or third-
degree AV block or a ventricular pause >3 s (with the possible exception of young trained persons, during sleep or rate-
controlled atrial fibrillation), or rapid prolonged paroxysmal SVT or VT are detected.185,188,197–199
IIa C
Additional advice and clinical perspectives
• Be aware that the pre-test selection of the patients influences the subsequent findings. Include patients with a high likelihood of arrhythmic
events. The duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of
syncope.158–160,183
• Exclude patients with a clear indication for ICD, pacemaker, or other treatments independent of a definite diagnosis of the cause of syncope.
• Include patients with a high probability of recurrence of syncope in a reasonable time. Owing to the unpredictability of syncope recurrence, be
prepared to wait up to 4 years or more before obtaining such a correlation.203
• In the absence of a documented arrhythmia, presyncope cannot be considered a surrogate for syncope, whereas the documentation of a signifi-
cant arrhythmia at the time of presyncope can be considered a diagnostic finding.199
• The absence of arrhythmia during syncope excludes arrhythmic syncope.
AV = atrioventricular; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
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are not low; adding an EEG increases the diagnostic probability of
PPS even further. The method has been proven to show the com-
bined presence of VVS and PPS.117
4.2.5.2 Home video recording
Home video records (by means of smartphone technology) are very
useful in all forms of TLOC to allow signs of an attack to be studied.
Patients and their relatives should be urged to record attacks, if possi-
ble, in cases of diagnostic uncertainty. In epilepsy, advances are made
towards prolonged video and EEG recording in patients’
homes.206,207 For syncope or PPS, experience suggests that the chan-
ces of obtaining a video record are higher for PPS than for syncope,
which is probably the effect of a high frequency and long duration of
attacks in PPS. It is rare for the beginning of events to be recorded.206
Home video records allow complex events such as syncope-induced
epileptic seizures to be diagnosed.208
4.2.6 Electrophysiological study
Indications: In an overview of eight studies, including 625 patients
with syncope undergoing EPS,209 positive results occurred predomi-
nantly in patients with structural heart disease. In recent years, the
development of powerful non-invasive methods, i.e. prolonged ECG
monitoring, showing a higher diagnostic value, has decreased the
importance of EPS as a diagnostic test. In clinical practice, registry data
show that approximately 3% of patients with unexplained syncope
evaluated by cardiologists undergo EPS and even fewer if they are
evaluated by other specialists.71 Nevertheless, EPS remains useful for
diagnosis in the following specific clinical situations: asymptomatic
sinus bradycardia (suspected sinus arrest causing syncope), bifascicu-
lar BBB (impending high-degree AV block), and suspected
tachycardia.
Diagnostic criteria: 4.2.6.1 Asymptomatic sinus bradycardia: sus-
pected sinus arrest causing syncope
The pre-test probability of bradycardia-related syncope is relatively
high when there is asymptomatic sinus bradycardia (<50 b.p.m.) or
sinoatrial block, usually documented by 12-lead ECG or ECG moni-
toring. The prognostic value of a prolonged sinus node recovery time
(SNRT) is not well defined. An abnormal response is defined as >_1.6
or 2 s for SNRT, or >_525 ms for corrected SNRT.210 One observatio-
nal study showed a relationship between the presence of prolonged
SNRT at EPS and the effect of pacing on symptoms.211 Another small
prospective study showed that a corrected SNRT >_800 ms had an
eight-fold higher risk of syncope than a SNRT below this value.212
4.2.6.2 Syncope in bifascicular bundle branch block (impending high-
degree atrioventricular block)
Patients with bifascicular block and syncope are at higher risk of devel-
oping high-degree AV block.213 A prolonged HV interval >_70 ms, or
induction of second- or third-degree AV block by pacing or by phar-
macological stress (ajmaline, procainamide, or disopyramide), identi-
fies a group at higher risk of developing AV block. By combining the
above-mentioned parts of the electrophysiological protocol, a positive
EPS yielded a positive predictive value as high as >_80% for the identifi-
cation of patients who will develop AV block in old studies.214–216
This finding has been indirectly confirmed by recent studies that
showed a significant reduction in syncopal recurrences in patients
with prolonged HV implanted with a pacemaker compared with a
control group of untreated patients with a negative EPS188, or with a
control group who received an empiric pacemaker.217 These results
justify an upgrade of the recommendation for EPS-guided therapy (i.e.
cardiac pacing) in patients with a positive EPS from class IIa to class I.
Even if the quality of evidence is moderate, there is strong con-
sensus that a positive EPS indicates that the likely mechanism
of syncope is paroxysmal AV block.
Conversely, approximately one-third of patients with a negative EPS in
whom an ILR was implanted developed intermittent or permanent AV
block on follow-up.187 Thus, EPS has a low negative predictive value.
Mortality is high in patients with syncope and BBB. However, neither
syncope nor prolonged H-V interval were associated with a higher risk
of death, and pacemaker therapy did not decrease this risk.213
4.2.6.3 Suspected tachycardia
In patients with syncope preceded by a sudden onset of brief palpita-
tions suggesting SVT or VT, an EPS may be indicated to assess the
exact mechanism, especially when a curative catheter ablation proce-
dure is considered to be beneficial.
In patients with a previous myocardial infarction and preserved left
ventricular ejection fraction (LVEF), induction of sustained mono-
morphic VT is strongly predictive of the cause of syncope,218
whereas the induction of ventricular fibrillation (VF) is considered a
non-specific finding.37 The absence of induction of ventricular
arrhythmias identifies a group at lower risk of arrhythmic syncope.219
The role of EPS and the use of pharmacological challenge by
class I antiarrhythmic drugs in patients with syncope and sus-
pected Brugada syndrome is controversial. In a recent meta-analy-
sis,220 the risk of arrhythmic events was slightly increased in
patients with a history of unexplained syncope or a spontaneous
type 1 pattern, and who had induction of VT or VF with one or
two extra stimuli. However, the absence of induction in such indi-
viduals does not necessarily preclude arrhythmia risk, particularly
in patients with high-risk features.
Video recording in suspected syncope
Recommendations Classa Levelb
Home video recordings of spontaneous
events should be considered. Physicians
should encourage patients and their rel-
atives to obtain home video recordings
of spontaneous events.206,208
IIa C
Adding video recording to tilt testing
may be considered in order to increase
the reliability of clinical observation of
induced events.9,116,117,205
IIb C
aClass of recommendation.
bLevel of evidence.
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4.2.7 Endogenous adenosine and other biomarkers
Established cardiac biomarkers such as troponin and B-type natriu-
retic peptide have been used to distinguish cardiac from non-cardiac
syncope and identify structural heart disease.223–225
4.2.7.1 Adenosine (triphosphate) test and plasma concentration
The purinergic signalling system, including adenosine and its
receptors, has been proposed to be involved in unexplained
syncope without prodrome.4,226 A low plasma adenosine level is
associated with paroxysmal AV block or CSS, whereas a high
level is seen in those with a hypotensive/vasodepressive tendency
and VVS. In parallel, the adenosine/adenosine triphosphate
(ATP) provocation test has been performed to demonstrate the
utility of adenosine sensitivity and paroxysmal cardioinhibitory
propensity for the selection of appropriate pacemaker candi-
dates.4,227,228 The test requires rapid (<2 s) injection of a 20 mg
bolus of ATP/adenosine during ECG monitoring. The induction of
AV block with ventricular asystole lasting >6 s, or the induction
of AV block lasting >10 s, is considered abnormal. ATP testing
was positive in most patients with syncope of unknown origin
(especially syncope without prodrome and without structural
heart disease4) but not in controls, suggesting that paroxysmal AV
Electrophysiological study
Recommendations Classa Levelb
Indications
In patients with syncope and previous myocardial infarction, or other scar-related conditions, EPS is indicated when syn-
cope remains unexplained after non-invasive evaluation.218
I B
In patients with syncope and bifascicular BBB, EPS should be considered when syncope remains unexplained after non-inva-
sive evaluation.188,214–217,221
IIa B
In patients with syncope and asymptomatic sinus bradycardia, EPS may be considered in a few instances when non-invasive
tests (e.g. ECG monitoring) have failed to show a correlation between syncope and bradycardia.210–212
IIb B
In patients with syncope preceded by sudden and brief palpitations, EPS may be considered when syncope remains unex-
plained after non-invasive evaluation.
IIb C
EPS-guided therapy
In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V
interval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological
challenge.188,214–217,221
I B
In patients with unexplained syncope and previous myocardial infarction, or other scar-related conditions, it is recom-
mended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46
I B
In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that
the induction of rapid SVT or VT, which reproduce hypotensive or spontaneous symptoms, is managed with appropriate
therapy according to the current ESC Guidelines.46,222
I C
In patients with syncope and asymptomatic sinus bradycardia, a pacemaker should be considered if a prolonged corrected
SNRT is present.210–212
IIa B
Additional advice and clinical perspectives
• In general, whereas a positive EPS predicts the cause of syncope, a negative study is unable to exclude an arrhythmic syncope and further evalua-
tion is warranted.
• The induction of polymorphic VT or VF in patients with ischaemic cardiomyopathy or DCM cannot be considered a diagnostic finding of the
cause of syncope.
• EPS is generally not useful in patients with syncope, normal ECG, no heart disease, and no palpitations.
BBB = bundle branch block; DCM = dilated cardiomyopathy; ECG = electrocardiogram; EPS = electrophysiological study; ESC = European Society of Cardiology; SNRT = sinus
node recovery time; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VF = ventricular fibrillation; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines 27
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..block could be the cause of unexplained syncope. Although car-
diac pacing may lead to substantial reduction of syncopal attacks
in elderly patients with unexplained syncope and a positive ATP
test,229 previous studies showed no correlation between
AV block induced by ATP and ECG findings (documented by ILR)
during spontaneous syncope.122,123,227 Thus, the low predictive
value of the test does not support its routine use in selecting
patients for cardiac pacing, but rather its positivity suggests that
it can be used to confirm the suspicion of asystolic syncope
by means of prolonged ECG monitoring. The role of endogenous
adenosine release in triggering a special form of asystolic
syncope (so-called adenosine-sensitive syncope) remains under
investigation.
4.2.7.2 Cardiovascular biomarkers
Some cardiovascular biomarkers are increased in autonomic dysfunc-
tion underlying syncope, such as elevated copeptin (vasopressin),
endothelin-1, and N-terminal pro-B-type natriuretic peptide in
OH,113,230,231 whereas atrial natriuretic peptide may be reduced in
POTS.113 At present, the use of cardiovascular biomarkers in the
diagnosis of syncope awaits more evidence and verification in inde-
pendent cohorts.
4.2.7.3 Immunological biomarkers
Autoantibodies against adrenergic receptors in OH and POTS have
been reported, but further studies are needed.232–234
4.2.8 Echocardiography
For patients with suspected heart disease, echocardiography serves
to confirm or refute the suspicions in equal proportions and plays an
important role in risk stratification.235,236 Echocardiography identifies
the cause of syncope in very few patients when no more tests are
needed (i.e. severe aortic stenosis, obstructive cardiac tumours or
thrombi, pericardial tamponade, or aortic dissection).237–239 In a lit-
erature review, right and left atrial myxoma presented with syncope
in <20% of cases.240–244
4.2.8.1 Exercise stress echocardiography
Upright or semi-supine exercise stress echocardiography to detect
provocable left ventricular outflow tract obstruction should be con-
sidered in patients with HCM that complain of exertional or postural
syncope, particularly when it recurs during similar circumstances (e.g.
when rushing upstairs or straining). A gradient of >_50 mmHg is usu-
ally considered to be the threshold at which left ventricular outflow
tract obstruction becomes haemodynamically important.245–249
Echocardiography
Recommendations Classa Levelb
Indications
Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 I B
Two-dimensional and Doppler echocardiography during exercise in the standing, sitting, or semi-supine position to detect
provocable left ventricular outflow tract obstruction is indicated in patients with HCM, a history of syncope, and a resting
or provoked peak instantaneous left ventricular outflow tract gradient <50 mmHg.245–249
I B
Diagnostic criteria
Aortic stenosis, obstructive cardiac tumours or thrombi, pericardial tamponade, and aortic dissection are the most prob-
able causes of syncope when the ECG shows the typical features of these conditions.237–244
I C
Additional advice and clinical perspectives
• For patients without suspected cardiac disease after history taking, physical examination, and electrocardiography, the ECG does not provide
additional useful information, suggesting that syncope alone is not an indication for echocardiography.
• Computed tomography or MRI should be considered in selected patients presenting with syncope of suspected cardiac structural origin when
echocardiography is not diagnostic.
ECG = echocardiogram; HCM = hypertrophic cardiomyopathy; MRI = magnetic resonance imaging.
aClass of recommendation.
bLevel of evidence.
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4.2.9 Exercise stress testing
Exercise-induced syncope is infrequent, and the literature is lim-
ited to case reports. Exercise testing should be performed in
patients who have experienced episodes of syncope during or
shortly after exertion. Syncope can occur during or immediately
after exercise. These two situations should be considered sepa-
rately. Indeed, syncope occurring during exercise is likely due to
cardiac causes (even though some case reports have shown that it
might be a manifestation of an exaggerated reflex vasodilatation),
whereas syncope occurring after exercise is almost invariably due
to a reflex mechanism.250–252 Tachycardia-related exercise-
induced second- and third-degree AV block has been shown to be
located distal to the AV node253 and predicts progression to per-
manent AV block.254,255 A resting ECG frequently shows intraven-
tricular conduction abnormalities,253,254 but cases with a normal
resting ECG have also been described.256,257 There are no data
supporting an indication for exercise testing in a general popula-
tion with syncope.
4.2.10 Coronary angiography
In patients presenting with syncope and obstructive coronary artery
disease, percutaneous coronary intervention is not associated with a
significant reduction in readmission for syncope.258 Angiography
alone is not diagnostic of the cause of syncope. Therefore, cardiac
catheterization techniques should be carried out in suspected myo-
cardial ischaemia or infarction with the same indications as for
patients without syncope.
5. Treatment
5.1 General principles of treatment of
syncope
The general framework of treatment is based on risk stratification
and the identification of specific mechanisms when possible (Figure 8).
The following three general principles should be considered:
• The efficacy of therapy aimed at preventing syncope recurrence
is largely determined by the mechanism of syncope rather than
its aetiology. Bradycardia is a frequent mechanism of syncope.
Cardiac pacing is the most powerful therapy for bradycardia but
its efficacy is less if hypotension coexists (see Table 9 and
Supplementary Data Table 9). The treatment of syncope due to a
hypotensive reflex or to OH is more challenging because specific
therapies are less effective.
• Often, therapy to prevent recurrence differs from that for the
underlying disease. The management of patients at high risk of
SCD requires careful assessment of the individual patient’s risk
(see section 5.5).
• Syncopal recurrences often decrease spontaneously after medical
assessment, even in the absence of a specific therapy; in general,
syncope recurs in <50% of patients within 1–2 years (see
Supplementary Data Table 10). The decrease seems to be more
evident when there is a lack of a clear anatomical substrate for
syncope, such as in the case of reflex syncope and unexplained
syncope. The reason for this decrease is not known. Several
potential clinical, statistical, and psychological explanations have
been provided and all probably play a role (see Supplementary
Data Table 10). Whatever the reason, the possibility of spontane-
ous improvement has major practical importance for treatment
that can be postponed in low-risk conditions. The consequence
of the spontaneous decrease is that any therapy for syncope pre-
vention appears to be more effective than it actually is, which
makes the results of observational data on therapy questionable
in the absence of a control group.
5.2 Treatment of reflex syncope
Despite its benign course, recurrent and unpredictable reflex syn-
cope may be disabling. The cornerstone of management of these
Exercise testing
Recommendations Classa Levelb
Indications
Exercise testing is indicated in patients who
experience syncope during or shortly after
exertion.
I C
Diagnostic criteria
Syncope due to second- or third-degree AV
block is confirmed when the AV block
develops during exercise, even without
syncope.253–257
I C
Reflex syncope is confirmed when syncope
is reproduced immediately after exercise in
the presence of severe hypotension.250–252
I C
Additional advice and clinical perspectives
There are no data supporting routine exercise testing in patients
with syncope.
AV = atrioventricular.
aClass of recommendation.
bLevel of evidence.
Coronary angiography
Recommendations Classa Levelb
Indications
In patients with syncope, the same indica-
tions for coronary angiography should be
considered as in patients without
syncope.258
IIa C
Additional advice and clinical perspectives
Angiography alone is not diagnostic of the cause of syncope.
aClass of recommendation.
bLevel of evidence.
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.patients is non-pharmacological treatment, including education,
lifestyle modification, and reassurance regarding the benign nature of
the condition.
Additional treatment may be necessary in patients with severe forms,
as defined in Web Practical Instructions section 2.3, in particular: when
very frequent syncope alters quality of life; when recurrent syncope
without, or with a very short, prodrome exposes the patient to a risk of
trauma; and when syncope occurs during a high-risk activity (e.g. driving,
machine operation, flying, or competitive athletics, etc.). Only 14% of
the highly selected population with reflex syncope who are referred to
specialized syncope units may need such additional treatment.186 In gen-
eral, no therapy is appropriate for every form of reflex syncope. The
most important discriminant for the choice of therapy is age. A decision
pathway for the selection of a specific therapy according to age, severity
of syncope, and clinical forms is summarized in Figure 9.
5.2.1 Education and lifestyle modifications
Education and lifestyle modifications have not been evaluated in
randomized studies, but there is a consensus for implementing them
as first-line therapy in all cases. These comprise reassurance about
the benign nature of the disease, education regarding awareness and the
possible avoidance of triggers and situations (e.g. dehydration and/or
hot crowded environments), and the early recognition of prodromal
symptoms in order to sit or lie down and activate counter-pressure
manoeuvres without delay. If possible, triggers should be addressed
directly, such as cough suppression in cough syncope, micturition in the
sitting position, etc. Increased intake of oral fluids is also advised. Salt
supplementation at a dose of 120 mmol/day of sodium chloride has
been proposed.259 In general, >50% of patients with recurrent syncopal
episodes in the 1 or 2 years before evaluation do not have syncopal
recurrences in the following 1 or 2 years and, in those with recurrences,
Table 9 Expected syncope recurrence rates with a permanent pacemaker in different clinical settings (for more
details see Supplementary Data Table 9).
Clinical setting Expected 2-year syncope recurrence rate
with cardiac pacing
Syncope due to established bradycardia and absence of hypotensive mechanism High efficacy (<_5% recurrence rate)
Syncope due to established bradycardia and associated hypotensive mechanism Moderate efficacy (5–25% recurrence rate)
Syncope due to suspected bradycardia and associated hypotensive mechanism Low efficacy (>25% recurrence rate)
Figure 8 General framework of treatment is based on risk stratification and the identification of specific mechanisms when possible. ARVC =
arrhythmogenic right ventricular cardiomyopathy; CAD = coronary artery disease; DCM = dilated cardiomyopathy; ECG = electrocardiographic;
HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; SCD = sudden cardiac death.
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the burden of syncope decreases by >70% compared with the
preceding period. The effect of education and reassurance is
probably the most likely reason for the decrease in syncope
(see Supplementary Data Table 10). An example of a patient instruction
sheet can be found in the Web Practical Instructions section 9.1: European
Society of Cardiology information sheet for patients affected by reflex
syncope.
Despite the lack of controlled studies, there is strong consensus
that education and lifestyle modifications have a high impact
in reducing recurrence of syncope.
5.2.2 Discontinuation/reduction of hypotensive therapy
Careful avoidance of agents that lower BP, i.e. any antihyperten-
sive agents, nitrates, diuretics, neuroleptic antidepressants, or
Figure 9 Schematic practical decision pathway for the first-line management of reflex syncope (based on patient’s history and tests) according to
age, severity of syncope, and clinical forms. Younger patients are those aged <40 years while older patients are >60 years, with an overlap between 40
and 60 years. Severity of reflex syncope is defined in the text. The duration of prodrome is largely subjective and imprecise. A value of <_5 s distinguishes
arrhythmic from reflex syncope49; in patients without structural heart disease, a duration >10 s can distinguish reflex syncope from cardiac syncope.38
In practice, the prodrome is ‘absent or very short’ if it does not allow patients enough time to act, such as to sit or lie down. The heading’ low BP phe-
notype’ identifies patients with chronic low BP values (in general, systolic around 110 mmHg, who have a clear history of orthostatic intolerance and
orthostatic VVS). The group ‘dominant cardioinhibition‘ identifies patients in whom clinical features and results of tests suggest that sudden cardioinhibi-
tion is mainly responsible for syncope. One such clue is lack of prodrome, so patients without prodromes may, after analysis, fall into this category.
Remark:
 Overlap between subgroups is expected.
 In selected cases, pacing may be used in patients aged <40 years. This Task Force cannot give recommendations due to the lack of
sufficient evidence from studies.
 In selected cases, fludrocortisone may be used in patients aged >60 years. This Task Force cannot give recommendations due to
the lack of sufficient evidence from studies.
 Midodrine can be used at any age even if existing studies were performed in young patients.
 Patients with short or no prodrome should continue investigations to identify the underlying mechanism and guide subsequent
therapy.
 Sometimes an ILR strategy should also be considered in patients aged <40 years.
BP = blood pressure; ILR = implantable loop recorder; VVS = vasovagal syncope.
aSpontaneous or provoked by, sequentially, carotid sinus massage, tilt testing, or ILR.
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dopaminergic drugs, is key in the prevention of recurrence of syn-
cope. In a small randomized trial260 performed in 58 patients
(mean age 74 ± 11 years) affected by vasodepressor reflex syn-
cope diagnosed by tilt testing or CSM, who were taking on average
2.5 hypotensive drugs, discontinuation or reduction of the vasoac-
tive therapy caused a reduction of the rate of the primary com-
bined endpoint of syncope, presyncope, and adverse events from
50 to 19% (hazard ratio 0.37) compared with a control group who
continued hypotensive therapy during a follow-up of 9 months. In
the Systolic Blood Pressure Intervention Trial,261 patients at high
cardiovascular risk who were already using antihypertensive drugs
targeting a systolic BP of 120 mmHg had an approximately two-
fold risk of syncope vs. the control group targeting a systolic BP of
140 mmHg. In a short-term randomized trial262 conducted in 32
patients affected by CSS, withdrawal of vasodilator therapy
reduced the magnitude of the vasodepressor reflex induced by
CSM.
There is moderate evidence that discontinuation/reduction of
hypotensive therapy targeting a systolic BP of 140 mmHg
should be effective in reducing syncopal recurrences in patients
with hypotensive susceptibility. Further research is likely to
have an important impact on our confidence in the estimate.
5.2.3 Physical counter-pressure manoeuvres
Isometric muscle contractions increase cardiac output and arterial BP
during the phase of impending reflex syncope. Three clinical stud-
ies119,120,263 and one prospective multicentre randomized trial121
assessed the effectiveness of physical counter-pressure manoeuvres
(PCM) of the legs or arms and showed that they allowed the patient
to avoid or delay losing consciousness in most cases. In the Physical
Counterpressure Manoeuvres Trial (PC-Trial),121 223 patients aged
38 ± 15 years with recurrent reflex syncope and recognizable pro-
dromal symptoms were randomized to receive standardized conven-
tional therapy alone or conventional therapy plus training in PCM.
Actuarial recurrence-free survival was better in the PCM group
(log-rank P=0.018), resulting in a relative risk reduction of 39% (95%
CI 11–53). No adverse events were reported. A limitation of this
treatment is that it cannot be used in patients with short or absent
prodrome and that PCM are less effective in patients older than 60
years.264 An instruction sheet on how to perform PCM can be found
in the Web Practical Instructions section 9.2.
There is moderate evidence that PCM is effective in reducing
syncopal recurrences in patients <60 years old with long-
lasting recognizable prodromal symptoms.
5.2.4 Tilt training
In highly motivated young patients with recurrent vasovagal symp-
toms triggered by orthostatic stress, the prescription of progressively
prolonged periods of enforced upright posture (so-called tilt training)
has been proposed to reduce syncope recurrence.265 While some
studies suggested modest benefit with outpatient tilt training,266,267
most controlled trials reported no significant effect.268–272
Moreover, this treatment is hampered by the low compliance of
patients in continuing the training programme for a long period.
There is sufficient evidence from multiple trials that tilt train-
ing has little efficacy in reducing recurrence of syncope in
young patients with long-lasting recognizable prodromal symp-
toms. Further research is unlikely to have an important impact
on our confidence in the estimate.
5.2.5 Pharmacological therapy
Pharmacological therapy may be considered in patients who have
recurrent syncope despite education and lifestyle modifications
including training in PCM. Many drugs have been tested in the treat-
ment of reflex syncope, for the most part with disappointing results.
While results have been satisfactory in uncontrolled trials or short-
term controlled trials, several long-term placebo-controlled prospec-
tive trials have not shown a benefit of the active drug over placebo,
with some exceptions.
5.2.5.1 Fludrocortisone
Fludrocortisone, by increasing renal sodium reabsorption and
expanding plasma volume, may counteract the physiological cascade
leading to the orthostatic vasovagal reflex.273 The mechanism of
action can be compared with that of saline infusion, which has also
proved effective in acute tilt test studies.274 The Prevention of
Syncope Trial (POST) 2275 enrolled 210 young (median age 30 years)
patients with low–normal values of arterial BP and without comor-
bidities, and randomized them to receive fludrocortisone (titrated at
a dosage of 0.05–0.2 mg once per day) or placebo. The primary end-
point showed only a marginal non-significant reduction in syncope in
the fludrocortisone group compared with the placebo group (hazard
ratio 0.69, 95% CI 0.46–1.03; P=0.069), which became more signifi-
cant when the analysis was restricted to patients who achieved 0.2
mg/day dose stabilization at 2 weeks. The clinical benefit of fludrocor-
tisone therapy was modest: at 12 months, 44% of patients in the flu-
drocortisone arm continued to suffer syncope, a rate only slightly
lower than the 60.5% rate observed in the placebo arm. In the mean-
time, a similar number of patients discontinued fludrocortisone ther-
apy owing to side effects, thus equating the benefit/risk ratio.
Fludrocortisone should not be used in patients with hypertension or
heart failure. Fludrocortisone was ineffective in a small randomized
double-blind trial in children.276
There is moderate evidence that fludrocortisone may be effec-
tive in reducing syncopal recurrences in young patients with
lownormal values of arterial BP and without comorbidities.
Further research is likely to have an important impact on our
confidence in the estimate of effect.
5.2.5.2 Alpha-agonists
As failure to achieve proper vasoconstriction of the peripheral ves-
sels is common in reflex syncope, alpha-agonist vasoconstrictors (eti-
lefrine and midodrine) have been used. Etilefrine has been studied in
a large randomized placebo-controlled double-blind trial.277 During
follow-up, patients treated twice daily with etilefrine 25 mg or pla-
cebo showed no difference in the frequency of syncope or the time
to recurrence. Midodrine [usually 2.5–10 mg, three times daily (t.i.d)]
has proved effective in small studies but none satisfied the criteria of
a pivotal clinical trial. A recent systematic review of these trials278
32 ESC Guidelines
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showed that the confidence in estimates was moderate because of
imprecision and publication bias. The most frequent side effects that
led to discontinuation of midodrine were supine hypertension, pilo-
motor reactions, and urinary problems (urinary retention, hesitancy,
or urgency). The major limitation of midodrine is frequent dosing,
which limits long-term compliance. Overall, these data suggest that
chronic pharmacological treatment with alpha-agonists alone may be
of little use in reflex syncope and that long-term treatment cannot be
advised for occasional symptoms.
There are contrasting results from multiple trials that alpha-
agonists may be effective in reducing syncopal recurrences in
patients with the orthostatic form of VVS. Further research is
likely to have an important impact on our confidence in the
estimate.
5.2.5.3 Beta-blockers
Beta-blockers have been presumed to lessen the degree of ventricu-
lar mechanoreceptor activation owing to their negative inotropic
effect in reflex syncope. This theory has not been supported by the
outcome of clinical trials. Beta-blockers failed to be effective in VVS
in two randomized double-blind controlled trials.279,280 A rationale
for the use of beta-blockers in other forms of neutrally-mediated syn-
cope is lacking. It should be emphasized that beta-blockers may
enhance bradycardia in CSS.
There is sufficient evidence from multiple trials that beta-
blockers are not appropriate in reducing syncopal recurrences.
Desirable and undesirable effects are closely balanced.
5.2.5.4 Other drugs
Paroxetine, a selective serotonin reuptake inhibitor, was effective in
one placebo-controlled trial, which included highly symptomatic
patients from one institution.281 This finding has not been confirmed
in other studies and has no experimental support. Conversely,
human studies with different subtypes of serotonin-receptor antago-
nists demonstrated a decreased tolerance to tilt.1,282 In a small
randomized trial, benzodiazepine was as effective as metoprolol.283
A somatostatin analogue (octreotide)284 was used in a few patients
affected by orthostatic intolerance and its effect cannot be properly
evaluated.
5.2.5.5 Emerging new therapies in specific subgroups
Low-adenosine phenotype. In a series of case reports, theophylline
appeared effective in patients with recurrent sudden onset (pre)syn-
cope who presented with the common biological characteristic of
low circulating adenosine levels.285,286 Theophylline is a non-selective
adenosine receptor antagonist that is potentially effective when
adenosine is suspected to be involved in the mechanism of syncope.
An intra-patient comparison between a period with and a period
without theophylline therapy, with the support of prolonged ECG
monitoring, showed that symptoms disappeared and the number of
prolonged asystolic pauses was impressively reduced from a median
of 1.11 per month during 13 months of no treatment to 0 per month
during 20 months of theophylline treatment.
Low-norepinephrine phenotype. A mismatch between sympathetic
nerve activity and norepinephrine spillover is present in patients with
orthostatic VVS.287 Norepinephrine transport inhibitors (reboxetine
and sibutramine) lead to a selective increase in sympathetic tone dur-
ing stress by inhibiting the reuptake of norepinephrine in sympathetic
neuronal synapses. In double-blind, randomized, crossover fashion,
reboxetine and sibutramine block or attenuate the vasovagal reflex
during tilt testing.288 In an open-label prospective clinical study in
seven very symptomatic patients who had not responded to any pre-
vious treatment, sibutramine achieved 94% suppression of syncopal
episodes at 6 months.289
Ganglionic plexus ablation. Radiofrequency ablation of vagal ganglia
located close to the sinus node and AV node was reported to abolish
the vagal efferent output during VVS in some observational studies
and case reports.290,291 However, owing to a weak rationale, small
populations, weak documentation of follow-up results, procedural
risks, and lack of control groups, the current evidence is insufficient
to confirm the efficacy of vagal ganglia ablation.
5.2.6 Cardiac pacing
Permanent pacemaker therapy may be effective if asystole is a domi-
nant feature of reflex syncope. Establishing a relationship between
symptoms and bradycardia should be the goal of the clinical evalua-
tion of patients with syncope and a normal baseline ECG. The efficacy
of pacing depends on the clinical setting. A comparative table of
results in different settings is reported in the Supplementary Data
Table 9. Figure 10 summarizes the recommended indication for
pacing.
5.2.6.1 Evidence from trials in suspected or certain reflex syncope and
electrocardiogram-documented asystole
In two observational studies, cardiac pacing reduced syncope burden
in patients with documented asystolic syncope by 92184 and 83%,200
but did not prevent all syncopal events. In the randomized
double-blind Third International Study on Syncope of Uncertain
Etiology (ISSUE)-3 trial,185 77 patients who had documentation, by
means of ILR, of syncope with >_3-s asystole or >_6-s asystole without
syncope were randomly assigned to receive either dual-chamber pac-
ing with rate drop response or sensing only. During follow-up, the 2-
year estimated rate of syncope recurrence was 57% with pacemaker
off and 25% with pacemaker on (log-rank P¼0.039). The risk of
recurrence was reduced by 57%. In the ILR subgroup of the multi-
centre Syncope Unit Project (SUP) 2 study,292 the estimated rates of
syncope recurrence with pacing were 11% at 1 year, 24% at 2 years,
and 24% at 3 years, and were significantly lower than the correspond-
ing rates observed in untreated control patients. The above evidence
supports a class IIa recommendation
There is sufficient evidence that dual-chamber cardiac pacing
should be considered to reduce recurrence of syncope when
the correlation between symptoms and ECG is established in
patients 40 years of age with the clinical features of those in
the ISSUE studies.
5.2.6.2 Evidence from trials in patients with carotid sinus syndrome
The evidence supporting the benefit of cardiac pacing in patients
affected by cardioinhibitory CSS is limited to a few small controlled
trials and retrospective observational studies. In a review293 including
ESC Guidelines 33
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..12 studies for a total of 601 paced and 305 unpaced patients, the syn-
copal recurrence rate during follow-up ranged from 0–20% with pac-
ing, whereas the recurrence of syncope was always higher in
untreated patients, who showed a rate between 20–60%. In a meta-
analysis of the three studies293 with a control group of untreated
patients, syncope recurred in 9% of 85 paced patients and in 38% of
91 controls (relative risk 0.24, 95% CI 0.12–0.48). In a single-centre
registry of 169 consecutive patients treated with pacemakers, the
actuarial estimate of syncopal recurrence was 7% at 1 year, 16% at
3 years, and 20% at 5 years.90 In the CSS subgroup of the multicentre
SUP 2 study,292 the estimated syncope recurrence rates with pacing
were 9% at 1 year, 18% at 2 years, and 20% at 3 years, and were signif-
icantly lower than the corresponding rates observed in untreated
controls, which were 21%, 33%, and 43%, respectively. Given the
similar outcome of patients with reflex spontaneous asystolic pauses
and those with CSS, this Task Force voted to downgrade the recom-
mendation for pacing in patients with CSS from class I (as in the 2013
ESC Pacing Guidelines294) to class IIa.
Despite the lack of large RCTs, there is sufficient evidence that
dual-chamber cardiac pacing should be considered to reduce
syncopal recurrences in patients affected by dominant cardi-
oinhibitory CSS.
Two variables are well known to hamper the efficacy of pacing ther-
apy in CSS: the mixed forms93,98 (see also Web Practical Instructions
section 5) and the association with positivity of tilt testing. Patients
who have positive tilt tests have a three-fold greater probability of
syncope recurrence after dual chamber pacing than those with nega-
tive tilt tests293,295; thus, when tilt testing is positive, caution must be
recommended over pacemaker implantation.
5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal
syncope
Effectiveness of pacing in patients with tilt-induced VVS has been
studied in five multicentre RCTs.296–300 When combining the results
of these trials, 318 patients were evaluated; syncope recurred in 21%
of the paced patients and in 44% of unpaced patients (P < 0.001). A
meta-analysis of all studies suggested a non-significant 17% reduction
in syncope from the double-blind studies, and an 84% reduction in
the studies where the control group did not receive a pacemaker.301
In general, pacing was ineffective in trials that enrolled patients with-
out an asystolic tilt response.299,300 All of these studies have limita-
tions, and a direct comparison is somewhat difficult because of
important differences in study design, largely focused on patient
selection. Overall, in typical vasovagal populations, pacing seems to
have marginal efficacy.
The rationale for the efficacy of cardiac pacing is that the cardioin-
hibitory reflex is dominant in some patients, as there is no role for
pacing in the preventing vasodilatation and hypotension. In a substudy
of the ISSUE-3 trial,302 an asystolic response during tilt testing pre-
dicted a similar asystolic form during spontaneous ILR-documented
syncope, with a positive predictive value of 86%. In the tilt subgroup
of the SUP 2 study,292 among 38 patients with dominant cardioinhibi-
tory reflex (with a mean asystolic pause of 22 ± 16 s) the estimated
rates of syncope recurrence with pacing were 3% at 1 year, 17% at 2
years, and 23% at 3 years; these figures were significantly lower than
the corresponding rates observed in untreated controls, and were
similar to those observed in patients with CSS or with ECG-
documented asystole. In a recent multicentre crossover RCT per-
formed in 46 patients aged >40 years, affected by severely recurrent
(>5 episodes during life) cardioinhibitory VVS,303 during 24-month
follow-up, syncope recurred in 4 (9%) patients treated with a dual-
Figure 10 Summary of indications for pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome.
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chamber pacemaker with closed-loop stimulation compared with 21
(46%) patients who had received a sham pacemaker programmed off
(P=0.0001).
Adding video recording to tilt testing, Saal et al.205 recently
showed, in patients with asystole, that asystole occurred 3 s
before syncope or later in one-third of patients, in whom cardioinhi-
bition was too late to have primarily caused syncope; in the other
two-thirds of asystolic tilt responses, the cause must have been
mainly cardioinhibition or a combination of cardioinhibition and
vasodepression.
The clinical presentation is probably as important as tilt test
positivity when selecting patients who can benefit from cardiac
pacing. The SUP 2 study population was characterized by higher
mean age, history of recurrent syncope beginning in middle or
older age, and frequent injuries, probably due to presentation
without warning.292
Owing to the contrasting results of the randomized trials, the
estimated benefit of dual-chamber pacing in cardioinhibitory
tilt-positive patients is weak. Divergence of opinion exists
among experts. Further research is very likely to have an
important impact on recommendations. Conversely, there is
strong consensus that pacing cannot be offered to patients
with non-cardioinhibitory tilt-positive response, and further
tests (e.g. ILR) are warranted to document the mechanism of
the spontaneous reflex.
5.2.6.4 Evidence from trials in patients with adenosine-sensitive syncope
Under this term, classified as a non-classical form of reflex syn-
cope in Table 3, different clinical conditions are included, which
have a supposed role of adenosine in the genesis of syncope in
common.
A new clinical entity, called idiopathic AV block, has recently
been described in patients with a long history of syncope and in
whom paroxysmal AV block could be recorded at the time of syn-
cope recurrence.5 These patients had an otherwise normal heart
and no sign of conduction disease on ECG and EPS; they had very
low plasma adenosine levels and a high induction rate of transient
complete heart block during exogenous injections of adenosine.
No syncope recurrence was observed after permanent cardiac
pacing over very long periods of follow-up and there was no per-
manent AV block.
Similarly, the entity of ‘low-adenosine syncope’ has recently
been described in patients who have an otherwise unexplained
syncope with sudden onset without prodrome, a normal heart,
and normal ECG.4 The clinical, laboratory, and biological features
of these patients are similar to those observed in patients
affected by idiopathic paroxysmal AV block. Unlike in VVS, tilt
testing is usually negative.4,226 No syncope recurrence was
observed after permanent cardiac pacing in 10 patients who had
ECG documentation of asystolic pause due to sinus arrest or AV
block.286
In a small multicentre trial227 performed in 80 highly selected eld-
erly patients with unexplained unpredictable syncope who had a pos-
itive response to intravenous injection of a bolus of 20 mg of ATP,
dual-chamber cardiac pacing significantly reduced the 2-year syncope
recurrence rate from 69% in the control group to 23% in the active
group.
There is weak evidence that dual-chamber cardiac pacing
may be useful in reducing recurrences of syncope in patients
with the clinical features of adenosine-sensitive syncope.
The documentation of possible bradyarrhythmia in sponta-
neous syncope remains the preferred eligibility criterion for
pacing.
5.2.6.5 Choice of pacing mode
In CSS, a few small controlled studies304,305 and one registry306
showed that dual-chamber pacing is better than the single chamber
ventricular mode in counteracting BP fall during CSM and in prevent-
ing symptom recurrences. Even if the quality of evidence is weak,
dual-chamber pacing is widely preferred in clinical practice.
In patients with VVS, dual-chamber pacing was used mostly with
a rate drop response feature that instituted rapid dual-chamber
pacing if the device detected a rapid decrease in HR. A compari-
son between dual-chamber closed-loop stimulation and conven-
tional dual-chamber pacing has been performed by means of a
crossover design in two small studies; these studies showed fewer
syncope recurrences with closed-loop stimulation, both in the
acute setting during repeated tilt testing307 and during 18-month
clinical follow-up.308
5.2.6.6 Selection of patients for pacing and proposed algorithm
The fact that pacing is effective does not mean that it is always neces-
sary. In patients with reflex syncope, cardiac pacing should be the last
choice and should only be considered in highly selected patients, i.e.
those >_40 years of age (mostly >60 years), affected by severe forms
of reflex syncope with frequent recurrences associated with a
high risk of injury, often due to the lack of prodrome.186 While there
is growing scepticism over the diagnostic accuracy of tilt testing for
syncope diagnosis, emerging evidence supports the use of tilt testing
for the assessment of reflex hypotensive susceptibility132, which may be
considered to identify patients with an associated hypotensive
response who would be less likely to respond to permanent cardiac
pacing (see section 4.2.2.2). In a meta-analysis309 of individual patient
data from four studies performed in patients with asystolic reflex
syncope documented by an ILR, the estimated 3-year recurrence
rate of syncope was 2% (95% CI ± 4%) in tilt-negative patients and
33% (95% CI ± 20%) in tilt-positive patients; a positive tilt test
response was the only significant predictor of syncope recurrence
with a hazard ratio of 4.3. Patients with hypotensive susceptibility
should need measures directed to counteract hypotensive suscepti-
bility in addition to cardiac pacing, e.g. the discontinuation/reduction
of hypotensive drugs and the administration of fludrocortisone or
midodrine.
The algorithm shown in Figure 11 has recently been prospectively
validated in a multicentre pragmatic study, which showed a low
recurrence rate of syncope with pacing of 9% at 1 year and 15% at 2
years, significantly lower than the 22% and 37%, respectively,
observed in unpaced controls.186
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Treatment of reflex syncope
Recommendations Classa Levelb
Education and lifestyle modifications
Explanation of the diagnosis, the provision of reassurance, and explanation of the risk of recurrence and the avoidance of
triggers and situations are indicated in all patients. Supplementary Data Table 10
I B
Discontinuation/reduction of hypotensive therapy
Modification or discontinuation of hypotensive drug regimen should be considered in patients with vasodepressor syncope,
if possible.260–262
IIa B
Physical manoeuvres
Isometric PCM should be considered in patients with prodromes who are <60 years of age.119–121,263,264 IIa B
Tilt training may be considered for the education of young patients.265–272 IIb B
Pharmacological therapy
Fludrocortisone may be considered in young patients with the orthostatic form of VVS, low–normal values of arterial BP,
and the absence of contraindication to the drug.275
IIb B
Midodrine may be considered in patients with the orthostatic form of VVS.278 IIb B
Beta-adrenergic blocking drugs are not indicated.279,280 III A
Cardiac pacing
Cardiac pacing should be considered to reduce syncopal recurrences in patients aged >40 years, with spontaneous docu-
mented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, AV block, or the combina-
tion of the two.184,185,200,292
IIa B
Cardiac pacing should be considered to reduce syncope recurrence in patients with cardioinhibitory carotid sinus syn-
drome who are >40 years with recurrent frequent unpredictable syncope.90,292,293
IIa B
Cardiac pacing may be considered to reduce syncope recurrences in patients with tilt-induced asystolic response who are
>40 years with recurrent frequent unpredictable syncope.292,297,298,303
IIb B
Cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensi-
tive syncope.5,227,286
IIb B
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.299,300 III B
Additional advice and clinical perspectives
• In general, no therapy can completely prevent syncope recurrence during long-term follow-up. A decrease of the syncope burden is a reasonable
goal of therapy.
• The fact that pacing may be effective does not mean that it is also always necessary. It must be emphasized that the decision to implant a pace-
maker needs to be made in the clinical context of a benign condition that frequently affects young patients. Thus, cardiac pacing should be limited
to a highly selected small proportion of patients affected by severe reflex syncope. Patients suitable for cardiac pacing are older with a history of
recurrent syncope beginning in middle or older age and with frequent injuries, probably due to presentation without warning. Syncope recur-
rence is still expected to occur despite cardiac pacing in a minority of patients.
• Tilt test response is the strongest predictor of pacemaker efficacy.309 Patients with a negative tilt test response will have a risk of syncope recur-
rence of as low as that observed in patients paced for intrinsic AV block. Further research is very unlikely to change the confidence in the esti-
mate of effect. On the contrary, patients with a positive tilt test response will have a higher risk of recurrence of syncope with a large confidence
range, which makes any estimate of the benefit of pacing uncertain. Further research is warranted.
AV = atrioventricular; BP = blood pressure; PCM = physical counter-pressure manoeuvres; VVS = vasovagal syncope.
aClass of recommendation.
bLevel of evidence.
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..5.3 Treatment of orthostatic hypotension
and orthostatic intolerance syndromes
Current management strategies for OH are summarized in Figure 12.
5.3.1 Education and lifestyle measures
Education regarding the nature of the condition in conjunction with the
lifestyle advice outlined in section 5.2.1 can markedly improve ortho-
static symptoms, even though the rise in BP is relatively small (10–15
mmHg); raising standing BP to just within the autoregulatory zone can
make a substantial functional difference. Ambulatory BP recordings may
be helpful in identifying abnormal diurnal patterns. These recordings may
also help identify supine or nocturnal hypertension in treated patients.
5.3.2 Adequate hydration and salt intake
The expansion of extracellular volume is an important goal. In the
absence of hypertension, patients should be instructed to have a sufficient
salt and water intake, targeting 2–3 L of fluids per day and 10 g of sodium
chloride.310 Rapid ingestion of cool water is reported to be effective in
combating orthostatic intolerance and postprandial hypotension.311
5.3.3 Discontinuation/reduction of vasoactive drugs
Several studies that have evaluated the association of vasoactive
drugs (i.e. any antihypertensive agents, nitrates, diuretics, neuroleptic
antidepressants, or dopaminergic drugs) with OH and falls
have yielded contrasting results.312 However, intensely prescribed
antihypertensive therapy can increase the risk of OH. Intensive anti-
hypertensive treatment can be defined as higher doses of antihyper-
tensive medications, an increased number of antihypertensive
drugs, or lowering BP to a target <140/90 mmHg. The total
number of BP-lowering medications313 or the use of three or more
antihypertensive drugs may be a significant predictor of OH.314
Angiotensin-converting enzyme inhibitors, angiotensin receptors
blockers, and calcium channel blockers are less likely to be associated
with OH compared with beta-blockers and thiazide diuretics.315–318
No
No
No
No
Asystolic
tilt testing?
Figure 11 Decision pathway for cardiac pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome; CSM = carotid
sinus massage; DDD PM = dual-chamber pacemaker; ILR = implantable loop recorder.
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.The principal treatment strategy in drug-induced autonomic
failure is eliminating the offending agent. The quality of evi-
dence is moderate. Longer-term future RCTs are likely to have
an important impact on determining the net risk2benefit ratio
of the withdrawal of culprit medications.
5.3.4 Counter-pressure manoeuvres
PCM such as leg crossing and squatting should be encouraged in
patients with warning symptoms who are able to perform them.319
5.3.5 Abdominal binders and/or support stockings
Gravitational venous pooling in older patients can be treated with
abdominal binders or compression stockings.23,320,321
5.3.6 Head-up tilt sleeping
Sleeping with the head of the bed elevated (>10 degrees) prevents
nocturnal polyuria, maintains a more favourable distribution of body
fluids, and ameliorates nocturnal hypertension.104,322,323
5.3.7 Midodrine
The alpha-agonist midodrine is a useful addition to first-line treatment
in patients with chronic autonomic failure. It cannot be regarded as a
cure, nor is it helpful in all affected patients, but it is very useful in
some. There is no doubt that midodrine increases BP both in the
supine and upright posture, and ameliorates the symptoms of OH.
Midodrine (2.5–10 mg t.i.d) was shown to be effective in three
randomized placebo-controlled trials.324–326
The desirable effects of midodrine outweigh the undesirable
effects. The quality of evidence is moderate and further research
is likely to have an important impact on the estimate of benefit.
5.3.8 Fludrocortisone
Fludrocortisone (0.1–0.3 mg once daily) is a mineralocorticoid that
stimulates renal sodium retention and expands fluid volume.327 The
evidence in favour of fludrocortisone is from two small observational
studies (in combination with head-up sleeping) and one double-blind
trial in 60 patients; the observational studies showed haemodynamic
benefit and, in the trial, treated patients were less symptomatic with
higher BP.322,327,328
The desirable effects of fludrocortisone outweigh the undesirable
effects. The quality of evidence is moderate and further research
is likely to have an important impact on the estimate of benefit.
5.3.9 Additional therapies
Additional and less frequently used treatments, alone or in combina-
tion, include desmopressin in patients with nocturnal polyuria,
octreotide in postprandial hypotension, erythropoietin in anaemia,
pyridostigmine, the use of walking sticks, frequent small meals, and
the judicious exercise of leg and abdominal muscles, especially swim-
ming. Their efficacy is less established.104
5.3.10 Emerging new pharmacological therapy in specific
subgroups
Droxidopa, a precursor of norepinephrine, is a centrally and periph-
erally acting alpha/beta-agonist approved by the US Food and Drug
Administration for the treatment of symptomatic neurogenic OH.
Droxidopa has recently been investigated for the treatment of neu-
rogenic OH in four short-term RCTs329–332 with a total of 485
patients. They showed a modest increase in standing systolic BP and
the symptom benefit of droxidopa over placebo regarding some
items of quality of life after 2 weeks of treatment, but its benefit was
Figure 12 Schematic practical guide for the treatment of orthostatic hypotension.
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lost after 8 weeks.333 Thus, current evidence is insufficient to confirm
the efficacy of droxidopa for long-term use.
5.4 Cardiac arrhythmias as the primary
cause
5.4.1 Syncope due to intrinsic sinoatrial or
atrioventricular conduction system disease
Current management strategies in patients with syncope due to
intrinsic cardiac bradycardia are summarized in Figure 13.
5.4.1.1 Sinus node disease
In general, cardiac pacemaker therapy is indicated and has proved
effective in intrinsic sinus node disease when intermittent sinus arrest
or sinoatrial block has been demonstrated to account for syncope by
means of ECG documentation during spontaneous syncope.334–338
A frequent situation is that of patients who have prolonged sinus
pause following the termination of tachycardia in bradycar-
dia-tachycardia syndrome due to the abnormally prolonged time
needed for the recovery of automaticity by a diseased sinus node.
Permanent pacing does not affect survival.
When the correlation between symptoms and ECG is estab-
lished, there is general consensus that cardiac pacing is effec-
tive and useful for symptom relief.
In the absence of the above situations, despite adequate pacing, syn-
cope recurs in approximately 15–28% of patients at 5 years339–341
(see Supplementary Data Table 9). This is due to the frequent associa-
tion of a vasodepressor reflex mechanism with sinus node disease. In
patients with sinus node disease and syncope, carotid sinus hypersen-
sitivity and a positive response to tilt are present in <_50% of patients.
Thus, an increased susceptibility to neurally mediated bradycardia/
hypotension is often the cause of syncope.135,136 A reflex mechanism
of syncope fits well with the unpredictable natural history of syncope
recurrence. Physicians should be aware that effectiveness of therapy is
not well documented in such cases. From a practical perspective, car-
diac pacing may be a reasonable solution in patients affected by sinus
node disease, who have had documentation of an asymptomatic ven-
tricular pause >3 s (with exceptions for young trained persons, during
sleep, and medicated patients), when a competitive diagnosis, i.e.
hypotension, can be ruled out.294 An abnormal SNRT enhances the
probability of efficacy of cardiac pacing (see section 4.2.6.1).210–212
When the correlation between symptoms and ECG is not
established, cardiac pacing may be reasonable in patients with
intrinsic sinus node disease, syncope, and documentation of
asymptomatic pause(s).
The elimination of drugs that may exacerbate or unmask an underly-
ing susceptibility to bradycardia is an important element in preventing
syncope recurrence. Percutaneous cardiac ablative techniques for
the control of atrial tachyarrhythmia have become of increasing
importance in selected patients with the bradycardia-tachycardia
form of sick sinus syndrome, but are infrequently used for the pre-
vention of syncope.
5.4.1.2 Atrioventricular conduction system disease
Cardiac pacing is the treatment of syncope associated with sympto-
matic AV block (Figure 13). Although formal RCTs of pacing in third-
or second-degree type 2 AV block have not been performed, some
observational studies suggest that pacing is highly effective in prevent-
ing syncope recurrences when AV block is documented. Langenfeld
et al.341 observed a decline in the rate of syncope from 44 to 3.4%
over 5-year follow-up in 115 patients paced for AV block; the recur-
rence rate was 7% in the subgroup with syncope before pacemaker
implantation. More recently, Sud et al.200 reported no syncope recur-
rence, and Aste et al.255 reported a recurrence of 1% at 5 years after
pacemaker implantation among 73 patients with documented
Treatment of orthostatic hypertension
Recommendations Classa Levelb
Explanation of the diagnosis, the provision
of reassurance, and explanation of the risk
of recurrence and the avoidance of triggers
and situations are indicated in all patients.
I C
Adequate hydration and salt intake are
indicated.310,311
I C
Modification or discontinuation of hypoten-
sive drug regimens should be
considered.312–318
IIa B
Isometric PCM should be considered.319 IIa C
Abdominal binders and/or support stockings
to reduce venous pooling should be
considered.23,320,321
IIa B
Head-up tilt sleeping (>10 degrees) to
increase fluid volume should be
considered.104,322,323
IIa C
Midodrine should be considered if symp-
toms persist.324–326
IIa B
Fludrocortisone should be considered if
symptoms persist.322,327,328
IIa C
Additional advice and clinical perspectives
• In individuals with established OH and risk factors for falls,
aggressive BP-lowering treatment should be avoided; their
treatment targets should be revised to a systolic BP value of
140–150 mmHg and medication withdrawal should be
considered.
• The BP-lowering agents (angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, and calcium channel
blockers) should be used preferentially, especially among
patients at high risk of falls, as diuretics and beta-blockers are
associated with OH and falls and should be avoided in at-risk
individuals.
BP = blood pressure; OH = orthostatic hypertension; PCM = physical counter-
pressure manoeuvres.
aClass of recommendation.
bLevel of evidence.
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..persistent or intermittent documented AV block (see Supplementary
Data Table 9).
5.4.1.3 Bundle branch block and unexplained syncope
The presence of bifascicular BBB suggests that the cause of syncope
may be complete heart block. Nevertheless, less than half of the
patients with bifascicular BBB and syncope will have a final diagnosis
of AV block, a similar percentage will have a final diagnosis of reflex
syncope, and, in approximately 15%, the cause will remain unex-
plained at the end of a complete workup.342 In addition, among
patients receiving an ILR, approximately half remained free of syn-
cope for >2 years after the implantation.187,188,342,343 Conversely,
implantation of a pacemaker without documentation of AV block
(empirical pacing) exposed patients to the risk of recurrence of syn-
cope in about one-quarter of cases during long-term follow-up and
was unnecessary in another half.217,344 Thus, only one in four pace-
makers will finally be appropriate. Finally, pacemaker treatment has
not been proven to have a survival benefit. The above considerations
justify a class IIb indication in the ESC Guidelines on pacing.294
To overcome the above problems, ESC Guidelines on pacing294—
in patients with LVEF >35%—recommend a strategy of EPS followed
by ILR if the EPS findings are unremarkable. With this strategy, a pace-
maker was implanted in approximately half of the patients and these
patients had syncope recurrence after pacemaker implantation in
0–7% of cases188,217. This strategy was safe; however, this Task Force
recognizes that in the ‘real world’, an empirical pacemaker may be
acceptable in selected patients at high risk of traumatic recurrence
(e.g. elderly patients with unpredictable syncopes) and that an individ-
ual risk–benefit evaluation is warranted (Figure 14).
Even if the quality of evidence is moderate, there is strong con-
sensus that in patients with bifascicular BBB with a positive EPS
or documentation of paroxysmal AV block during prolonged
ECGmonitoring, cardiac pacing is highly effective in preventing
syncope recurrence. The evidence of efficacy of empirical pac-
ing strategy is weak and the estimate of benefit is uncertain.
Although syncope is not associated with an increased incidence of sud-
den death in patients with preserved cardiac function, a high incidence
of total deaths (about one-third sudden) was observed in patients with
BBB and heart failure, previous myocardial infarction, or low ejection
fraction.345–347 Indeed, the high total and sudden mortality seems to be
mainly related to underlying structural heart disease and ventricular
tachyarrhythmias. In this latter situation, syncope is a risk factor, rather
than the cause, of death.218 Unfortunately, ventricular programmed
stimulation does not seem to identify these patients correctly, and the
finding of inducible ventricular arrhythmia (VA) should therefore be
interpreted with caution.345,346 Therefore, an implantable cardioverter
defibrillator (ICD) or a cardiac resynchronization therapy defibrillator is
indicated in patients with BBB, congestive heart failure, or previous
myocardial infarction and depressed systolic function for the preven-
tion of SCD, but may be unable to prevent the recurrence of syncope,
which is often due to non-arrhythmic causes such as OH or vasode-
pressor reflex. The strategy for the management of patients with unex-
plained syncope and BBB is summarized in Figure 14.
5.4.2 Syncope due to intrinsic cardiac tachyarrhythmias
Current management strategies in patients with syncope due to
intrinsic cardiac tachyarrhythmia are summarized in Figure 15.
° °
Figure 13 Summary of indications for pacing in patients with syncope due to intrinsic cardiac bradycardia. AF = atrial fibrillation; asympt. = asymp-
tomatic; AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiological study; HR = heart rate; ILR =
implantable loop recorder; SB = sinus bradycardia; SND = sinus node dysfunction; sympt. = symptomatic.
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5.4.2.1 Paroxysmal supraventricular tachycardia
In patients with paroxysmal AV nodal re-entrant tachycardia, AV re-
entrant tachycardia, typical atrial flutter, and ectopic tachycardia
associated with syncope, catheter ablation is the first-choice treat-
ment. In these patients, the role of drug therapy is limited to being a
bridge to ablation or being used when ablation has failed. In patients
with syncope associated with atrial fibrillation or atypical left atrial
flutter, the decision should be individualized.
5.4.2.2 Paroxysmal ventricular tachycardia
Syncope due to torsade de pointes is not uncommon and is, in its
acquired form, the result of drugs that prolong the QT interval.
Treatment is the immediate discontinuation of the suspected drug.
Catheter ablation or drug therapy is recommended in patients
with syncope due to VT in the presence or absence of structural
heart disease in order to prevent syncope recurrence (Figure 15).
Detailed guidelines regarding antiarrhythmic drug usage in patients
Figure 14 Therapeutic algorithm for patients presenting with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D
= cardiac resynchronization therapy defibrillator; EPS = electrophysiological study; ICD = implantable cardioverter defibrillator; ILR = implantable
loop recorder; PM = pacemaker.
Figure 15 Choice of therapy for patients presenting with syncope due to cardiac tachyarrhythmias as the primary cause. AA = antiarrhythmic;
ICD = implantable cardioverter defibrillator; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
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with VT can be found in the 2015 ESC Guidelines for VA and the pre-
vention of SCD.46
An ICD is indicated in patients with syncope and depressed cardiac
function, and VT or VF without correctable cause. Although ICD
may not prevent syncope recurrence in these patients,31,348 it is indi-
cated to reduce the risk of SCD (refer to the 2015 ESC Guidelines
for VA and the prevention of SCD46). An ICD is also indicated in
patients with syncope and previous myocardial infarction who have
VT induced during EPS346 (see section 4.2.6).
In patients with preserved systolic function, the indication for ICD
is weaker because trials have not addressed this specific issue.
However, when VT causes syncope, this Task Force believes that an
ICD is warranted if catheter ablation and pharmacological therapy
have failed or could not be performed (Figure 15).
Treatment of syncope due to cardiac arrhythmias
Recommendations Classa Levelb
Bradycardia (intrinsic)
Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic bradycardia due to:
• Sick sinus syndrome.210–212,334–338 I B
• Intrinsic AV block.200,255,341 I B
Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including
AF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECGs.
I C
Cardiac pacing should be considered when the relationship between syncope and asymptomatic sinus node dysfunction is
less established.135,136,210–212,339,340
IIa C
Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C
Bifascicular BBB
Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 I B
Cardiac pacing may be considered in patients with unexplained syncope and bifascicular BBB.217,255,344 IIb B
Tachycardia
Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence.46 I B
An ICD is indicated in patients with syncope due to VT and an ejection fraction <_35%.46 I A
An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS.218 I C
An ICD should be considered in patients with an ejection fraction >35% with recurrent syncope due to VT when catheter
ablation and pharmacological therapy have failed or could not be performed.46
IIa C
Antiarrhythmic drug therapy, including rate-control drugs, should be considered in patients with syncope due to SVT or VT. IIa C
Additional advice and clinical perspectives
• The major factors predicting the efficacy of pacing in preventing syncope recurrence are an established relationship between symptoms and bra-
dycardia and the absence of associated hypotensive susceptibility (Table 8 and Supplementary Data Table 9). When this relationship is less estab-
lished, or some hypotensive mechanism is present, syncope can recur in a minority of patients.
• Pacing is not indicated in unexplained syncope without evidence of any conduction disturbance.
• Less than half of the patients with bifascicular BBB and syncope have a final diagnosis of cardiac syncope, albeit the probability is different among the types
of BBB. We recommend conducting any useful investigation (e.g. CSM, EPS, or ILR) to provoke/document the mechanism of syncope before deciding to
implant a pacemaker or selecting the correct therapy.
• Elderly patients with bifascicular BBB and unexplained syncope after a reasonable workup might benefit from empirical pacemaker implantation,
especially if syncope is unpredictable (with no or short prodromes) or has occurred in the supine position or during effort.
• When indicated, ICD prevents SCD but it may be unable to prevent syncope due to VT recurrence.31,348 Thus, when syncope is due to VT
(including when the diagnosis is established by the induction of VT during EPS), catheter ablation should be always attempted when feasible in
addition to ICD implantation.
AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; CSM = carotid sinus massage; ECG = electrocardiogram; EPS = electrophysiological study; ICD =
implantable cardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
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5.5 Treatment of syncope secondary to
structural cardiac, cardiopulmonary, and
great vessel disease
Cardiac syncope is diagnosed when syncope presents in patients with
severe aortic stenosis, acute myocardial infarction/ischaemia, HCM,
cardiac masses (atrial myxoma, ball thrombus, etc.), pericardial dis-
ease/tamponade, congenital anomalies of the coronary arteries, pros-
thetic valve dysfunction, pulmonary embolus, acute aortic dissection,
and pulmonary hypertension (see section 4.1.1). Structural cardiac or
cardiopulmonary disease can be present in some patients with syn-
cope, and its incidence increases in older patients. The mere presence
of heart disease does not imply that syncope is related to the underly-
ing cardiac disorder. Some of these patients have typical reflex syn-
cope; in others, such as those with inferior myocardial infarction or
aortic stenosis, the underlying cardiac disease may play a role in trig-
gering or potentiating a reflex mechanism, and—finally—the underly-
ing cardiac disease may be the substrate for conduction disturbances,
supraventricular arrhythmia, or VA that causes syncope.
Even in the absence of specific trials, there is strong consensus
that with syncope secondary to structural cardiac disease, the
goal of treatment is not only to prevent syncopal recurrence, but
to treat the underlying disease and decrease the risk of death.
5.6 Treatment of unexplained syncope in
patients at high risk of sudden cardiac
death
The underlying clinical situation is that of a patient being evaluated for
ICD implantation because they are affected by syncope(s) supposedly
due to transient self-terminating ventricular tachyarrhythmias (fast VT or
VF), which have not yet been documented because of their short dura-
tion.349 Syncope due to documented VT/VF is outside the scope of this
section; please refer to section 5.4.2. General guidance may be sought in
the 2015 ESC Guidelines for VA and the prevention of SCD.46
5.6.1 Definition
In general, a history of syncope in patients with structural heart
disease or inheritable arrhythmia syndromes is associated with a
two- to four-fold increased risk of death,348,350–353 but varies
between specific conditions.354–356 Moreover, there have been
very few studies on ICDs in patients with syncope associated with
left ventricular dysfunction,31,348 cardiomyopathy, or inheritable
arrhythmia syndromes.357 In these Guidelines, we complement
previous ESC Guidelines for VA and the prevention of SCD46 by
providing a precise definition of unexplained syncope, and making
recommendations for its investigation and management in differ-
ent clinical settings.
• For this section, ‘unexplained syncope‘ is defined as syncope that
does not meet any class I diagnostic criterion defined in the
tables of recommendations in section 4. In the presence of clini-
cal features described in this section, unexplained syncope is con-
sidered a ‘suspected arrhythmic syncope’.
When the mechanism of syncope is non-arrhythmic, the manage-
ment of patients at high risk of SCD is the same as for patients with-
out syncope.
5.6.2 Left ventricular systolic dysfunction
The benefit of an ICD to reduce the risk of death is established. Thus,
patients with unexplained syncope who have an established ICD indi-
cation per current Guidelines46 must receive an ICD before, and
independently of, the evaluation of the mechanism of syncope, even if
the mechanism of syncope is unknown or uncertain at the end of a
complete workup. While this strategy may help to prolong life,
patients often remain at risk of recurrent syncope, implying a need
for precise identification of the mechanism of syncope and specific
treatment when possible.
Few data exist concerning the prevalence and the prognostic impli-
cations of unexplained syncope in unselected patients with left ven-
tricular dysfunction or non-ischaemic dilated cardiomyopathy with
Implantable cardioverter defibrillator indications in
patients with unexplained syncopea and left ventricular
systolic dysfunction
Recommendations Classb Levelc
ICD therapy is recommended to reduce
SCD in patients with symptomatic heart fail-
ure (NYHA class II–III) and LVEF <_35% after
>_3 months of optimal medical therapy, who
are expected to survive >_1 year with good
functional status.46
I A
An ICD should be considered in patients
with unexplained syncopea with systolic
impairment, but without a current indication
for ICD, to reduce the risk of sudden
death.27,28,359,360
IIa C
Instead of an ICD, an ILR may be considered
in patients with recurrent episodes of unex-
plained syncopea with systolic impairment,
but without a current indication for ICD.
IIb C
Additional advice and clinical perspectives
• The presence of syncope increases mortality regardless of its
cause.348 Thus, syncope is a risk factor for life-threatening
events.
• The decision to implant an ICD or to complete the
investigation (e.g. ILR implantation) in patients with unex-
plained syncope depends on a global clinical evaluation
of the patient’s conditions, the potential benefit and harm
of such therapy, and the presence of other risk factors
for SCD.
ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association;
SCD = sudden cardiac death.
aUnexplained syncope is defined as syncope that does not meet a class I diagnos-
tic criterion defined in the tables of recommendations in section 4. In the pres-
ence of clinical features described in this section, unexplained syncope is
considered a risk factor for ventricular tachyarrhythmias.
bClass of recommendation.
cLevel of evidence.
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..less severe systolic impairment who do not meet the current indica-
tion for ICD.358 Data from observational studies in selected cohorts
show a high rate of occurrence of ventricular arrhythmias, ICD dis-
charge, and death in patients with a history of unexplained syncope
but, owing to a lack of control groups, are unable to show the benefit
of an ICD.27,28,359,360 This Task Force believes that an ICD should be
considered in patients with unexplained syncope with systolic impair-
ment but without a current indication for ICD to reduce the risk of
sudden death.
5.6.3 Hypertrophic cardiomyopathy
Unexplained syncope is an independent predictor for SCD and
appropriate ICD discharge. In a systematic review, the average haz-
ard ratio of unexplained syncope (irrespective of definition) was 2.68
(95% CI 0.97–4.38).361 In the largest multicentre study to date
(>3600 patients with HCM), syncope was an independent predictor
of the composite of SCD and ICD discharge (hazard ratio 2.05, 95%
CI 1.48–2.82).350 A prophylactic ICD is appropriate in individuals
with other features indicative of a high risk of SCD that are used to
estimate the 5-year risk of SCD using the HCM Risk-SCD model245;
they include: age, family history of SCD, maximum left ventricular
wall thickness, left atrial diameter, and non-sustained VT.
5.6.4 Arrhythmogenic right ventricular
cardiomyopathy
Although limited and diverse, current data suggest that unexplained syn-
cope is a marker of arrhythmic risk in patients with ARVC.46,351,362,363
The decision to implant an ICD should take into account the other
known risk factors for arrhythmic events46: frequent non-sustained VT,
family history of premature sudden death, extensive right ventricular
disease, marked QRS prolongation, late gadolinium enhancement on
magnetic resonance imaging (MRI) (including left ventricular involve-
ment), left ventricular dysfunction, and VT induction during EPS.46
5.6.5 Patients with inheritable arrhythmogenic disorders
5.6.5.1 Long QT syndrome
Syncopal events in long QT syndrome (LQTS) are associated with an
increased risk of subsequent cardiac arrest. The annual rate of SCD in
patients with untreated LQTS is around 0.9% overall and 5% for those
with syncope.352,364 Beta-blocker therapy substantially reduces the risk
of syncope and SCD, but presentation with cardiac arrest and recur-
rent syncope during beta-blocker therapy is associated with the same
risk of fatal events as in untreated patients.46 For this reason, ICD treat-
ment should be considered in patients with LQTS and recurrent unex-
plained syncope despite beta-blocker therapy, especially in cases of
good treatment compliance, in the absence of precipitating factors,
and in LQT2 and LQT3 syndromes. Left cardiac sympathetic denerva-
tion should also be considered in this situation, particularly in LQT1.46
5.6.5.2 Brugada syndrome
A history of syncope may increase the risk of arrhythmic events up to
two- to three-fold compared with that in asymptomatic patients. In
the largest registry (1029 patients), the incidence of arrhythmic events
Implantable cardioverter defibrillator indications in
patients with unexplained syncopea and hypertrophic
cardiomyopathy
Recommendations Classb Levelc
It is recommended that decisions for ICD
implantation in patients with unexplained
syncopea are made according to the ESC
HCM Risk-SCD score.d,245
I B
Instead of an ICD, an ILR should be consid-
ered in patients with recurrent episodes of
unexplained syncopea who are at low risk of
SCD, according to the HCM Risk-SCD
score.d,245
IIa C
Additional advice and clinical perspectives
The decision to implant an ICD or to complete the investigation
(e.g. ILR implantation) in patients with unexplained syncope
depends on a global clinical evaluation of the patient’s condition,
the potential benefit and harm of such therapy, and the presence
of other risk factors for SCD.
ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy;
ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
SCD = sudden cardiac death.
aUnexplained syncope is defined as syncope that does not meet the class I diag-
nostic criterion defined in the tables of recommendations in section 4. In the
presence of clinical features described in this section, unexplained syncope is con-
sidered a risk factor for ventricular tachyarrhythmias.
bClass of recommendation.
cLevel of evidence.
dA web-based calculator of the HCM risk score can be found at: http://www.
doc2do.com/hcm/webHCM.html. It can also be found in the ESC Pocket
Guidelines App found in all app stores.
Implantable cardioverter defibrillator indications in
patients with unexplained syncopea and arrhythmogenic
right ventricular cardiomyopathy
Recommendations Classb Levelc
ICD implantation may be considered in
patients with ARVC and a history of unex-
plained syncope.a,46
IIb C
Instead of an ICD, an ILR should be consid-
ered in patients with recurrent episodes of
unexplained syncope who are at low risk of
SCD, based on a multiparametric analysis
that takes into account the other known
risk factors for SCD.
IIa C
ARVC = arrhythmogenic right ventricular cardiomyopathy; ICD = implantable
cardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden car-
diac death.
aUnexplained (or uncertain) syncope is defined any syncope that does not meet
class I diagnostic criteria defined in the tables of recommendations in section 4. In
the presence of clinical features described in this section, unexplained syncope is
considered a risk factor for ventricular tachyarrhythmias.
bClass of recommendation.
cLevel of evidence.
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..(sustained VT or VF, appropriate ICD therapy, or sudden death) in
patients with Brugada syndrome was 7.7% per year in those with a
history of sudden cardiac arrest, 1.9% per year with syncope, and
0.5% per year in asymptomatic patients.353 However, in a second
study, the rate of appropriate ICD shocks was similar in asymptomatic
patients and in those with syncope, a difference possibly explained by
patient selection and a high rate of non-arrhythmic syncope.355
On balance, this Task Force believes that it is reasonable to con-
sider an ICD in the case of unexplained syncope. New studies356,365
published after the 2015 ESC Guidelines for VA and the prevention of
SCD46 showed that non-arrhythmic syncope is frequent in Brugada
syndrome and appears to be more benign; thus, ICD should be
avoided in patients with non-arrhythmic syncope that is established
according to the definition reported in this section. ILR is increasingly
used in doubtful cases to exclude a VA as the cause of syncope.365,366
The final decision to implant an ICD in patients with Brugada syn-
drome and unexplained syncope should also take into account other
risk factors for arrhythmic events, including spontaneous type 1 Brugada
ECG pattern, family history of sudden death, VF inducibility with one or
two ventricular premature beats during EPS, fractionated QRS, early
repolarization in the peripheral leads, increased Tpeak–Tend interval, and
long PR interval.220,367–371 A drug-induced type 1 ECG pattern has a
lower risk of sudden death than a spontaneous type 1 response.
5.6.5.3 Other forms
Due to a lack of studies examining unexplained syncope in other forms
of inheritable arrhythmic diseases such as catecholaminergic polymor-
phic VT, early repolarization syndrome, and short QT syndrome, this
Task Force is unable to give specific recommendations for the investi-
gation and treatment of unexplained syncope. For further information
refer to the 2015 ESC Guidelines for VA and the prevention of SCD.46
6. Special issues
6.1 Syncope in patients with comorbidity
and frailty
The approach to the assessment and management of an older patient
with syncope is similar to that of other age groups; however, there
are a number of additional features pertinent to age-related comor-
bidity and frailty that warrant special attention.372–374
6.1.1 Comorbidity and polypharmacy
Comorbidity influences the diagnosis of syncope and management
decisions.33,375 Older patients frequently have abnormal findings on
more than one investigation and may have more than one possible
cause of syncope.372,374,376 Conversely, coincidental findings of
Implantable cardioverter defibrillator indications in
patients with unexplained syncopea and long QT
syndrome
Recommendations Classb Levelc
ICD implantation in addition to beta-blockers
should be considered in LQTS patients who
experience unexplained syncopea while
receiving an adequate dose of beta-blockers.46
IIa B
Left cardiac sympathetic denervation should
be considered in patients with symptomatic
LQTS when:
(1) beta-blockers are not effective, not tol-
erated, or are contraindicated;
(2) ICD therapy is contraindicated or
refused; or
(3) when patients on beta-blockers with an
ICD experience multiple shocks.46
IIa C
Instead of an ICD, an ILR should be consid-
ered in patients with recurrent episodes of
unexplained syncopea who are at low risk of
SCD based on a multiparametric analysis
that takes into account the other known
risk factors for SCD.
IIa C
Additional advice
Beta-blockers are recommended in all patients with a clinical diagno-
sis of LQTS, with the possible exception of those with LQTS3 form.
ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
LQTS = long QT syndrome; SCD = sudden cardiac death.
aUnexplained (or uncertain) syncope is defined as any syncope that does not
meet class I diagnostic criteria defined in the tables of recommendations in sec-
tion 4. In the presence of clinical features described in this section, unexplained
syncope is considered a risk factor for ventricular tachyarrhythmias.
bClass of recommendation.
cLevel of evidence.
Implantable cardioverter defibrillator indications in
patients with unexplained syncopea and Brugada
syndrome
Recommendations Classb Levelc
ICD implantation should be considered in
patients with a spontaneous diagnostic
type 1 ECG pattern and a history of
unexplained syncope.a,46,353,355,365,366
IIa C
Instead of an ICD, an ILR should be consid-
ered in patients with recurrent episodes of
unexplained syncopea who are at low risk of
SCD, based on a multiparametric analysis
that takes into account the other known
risk factors for SCD.
IIa C
ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; ILR =
implantable loop recorder; SCD = sudden cardiac death.
aUnexplained (or uncertain) syncope is defined as any syncope that does not
meet the class I diagnostic criteria defined in section 4. In the presence of clinical
features described in this section, unexplained syncope is considered a risk factor
for ventricular tachyarrhythmias.
bClass of recommendation.
cLevel of evidence.
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..cardiovascular diagnoses such as aortic stenosis or atrial fibrillation377
may not necessarily be the attributable cause of events.378–380
The prescription of polypharmacy, cardiovascular medications, and
psychotropic (neuroleptics and antidepressants) and dopaminergic
drugs also increases the risk of syncope and falls.381–385 Conversely,
the discontinuation or reduction of hypotensive therapy reduces such
risk.260 Negative dromotropic and chronotropic medications should
be carefully evaluated in older patients presenting with syncope or falls.
Focal neurological events can occasionally occur due to hypoten-
sion and syncope, even in patients without significant carotid artery
stenosis (so called ‘hypotensive TIA’). Although these neurological
events occur in only 6% of patients with recurrent syncope, their mis-
diagnosis is particularly important because they may lead to a lowering
of BP with antihypertensive medications (e.g. if focal neurology is mis-
takenly attributed to vascular pathology rather than hypotension), and
to a further increase of the risk of syncope and neurologic events.386
Despite the lack of large controlled trials and an overall mod-
est quality of studies, there is strong consensus that reduction
or discontinuation of hypotensive drugs and psychotropic drugs
clearly outweighs the undesirable effects (e.g. complications)
of high BP. Further research is likely to have an important
impact on our confidence in the estimate of effect.
6.1.2 Falls
Syncopal events may be unwitnessed in over half of older patients
meaning that collateral histories may not available, which makes discrim-
ination between falls and syncope challenging.387 If unwitnessed falls are
not due to mechanical slips or trips (i.e. are unexplained or non-
accidental), it is likely that the patient experienced a syncopal event and
displayed lack of awareness for LOC (Figure 16).388,389 Management of
falls in such circumstances is the same as that for syncope.191,194,390
Despite the lack of controlled trials and an overall modest
quality of studies, there is strong consensus that the manage-
ment of unexplained falls should be the same as that for unex-
plained syncope.
6.1.3 Cognitive assessment and physical performance tests
Age-related memory impairment or more established forms of cog-
nitive impairment are frequently associated with poor recall and
therefore the lack of an accurate history of events. In such circum-
stances, details of prodromal symptoms, whether or not LOC
occurred, and symptoms after the event may be unre-
liable.373,389,391–394 Cognitive assessment to inform the accuracy of
historical data, and general physical assessment to identify comorbid
disorders that influence diagnosis and response to treatments (such
as Parkinson’s disease, gait and balance abnormalities, previous
stroke, and polyneuropathies, etc.), are recommended.
Despite the lack of large controlled trials and an overall modest
quality of studies, there is strong consensus that the assessment
of older patients with syncope or unexplained falls may require
cognitive assessment and physical performance tests in addition
to syncope evaluation. Further research is likely to have an
important impact on our confidence in the estimate of effect.
Figure 16 Flow diagram for the identification of unexplained
falls.
Syncope in patients with comorbidity and frailty
Recommendations Classa Levelb
Multifactorial evaluation and intervention is
recommended in older patients because more
than one possible cause for syncope and unex-
plained fall may be present.33,372–374,376–380
I B
Cognitive assessment and physical perform-
ance tests are indicated in older patients with
syncope or unexplained fall.373,389,391–394
I C
Modification or discontinuation of possible culprit
medications, particularly hypotensive drugs and
psychotropic drugs, should be considered in older
patients with syncope or unexplained fall.260,381–385
IIa B
In patients with unexplained fall, the same
assessment as for unexplained syncope should
be considered.191,194,387–390
IIa C
Additional advice and clinical perspectives
• In some frail elderly patients, the rigour of assessment will depend
on compliance with tests and on prognosis. Otherwise, the evalu-
ation of mobile, non-frail, cognitively normal older adults must be
performed as for younger individuals.393,395
• Orthostatic BP measurements, CSM, and tilt testing are well tol-
erated, even in the frail elderly with cognitive impairment.96,396,397
• Not infrequently, patients who present with unexplained falls—
although orthostatic BP measurements, CSM, and tilt testing repro-
duce syncope—may deny TLOC, thus demonstrating amnesia for
TLOC.388,389
• Failure of orthostatic BP to stabilize is present in up to 40% of
community-dwelling people >80 years of age when BP is meas-
ured using phasic BP technology.398 Such failure of systolic BP to
stabilize is a risk factor for subsequent falls and syncope.
• In the absence of a witness account, the differential diagnosis
between falls, epilepsy, TIA, and syncope may be difficult.
BP = blood pressure; CSM = carotid sinus massage; TIA = transient ischaemic
attack; TLOC = transient loss of consciousness.
aClass of recommendation.
bLevel of evidence.
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6.2 Syncope in paediatric patients
6.2.1 Diagnostic evaluation
Diagnostic evaluation in paediatric patients is similar to that in adults.
Two specific conditions399 occur in early childhood:
• Infantile reflex syncopal attacks (also called pallid breath-holding
spells or reflex anoxic seizures), elicited by a brief unpleasant
stimulus, caused by vagally mediated cardiac inhibition.
• Cyanotic breath-holding spells, characterized by stopping
breathing during crying, leading to cyanosis and usually
TLOC.
Careful taking of personal and family history and a standard
ECG are the most important methods of distinguishing benign
reflex syncope (also including reflex anoxic seizure or breath-
holding spells) from other causes. If the family history is positive,
genetic causes of electrical disease of the heart should be consid-
ered first. Some children with reflex syncope also have a positive
family history.400 Tilt testing seems to have high false-negative and
false-positive rates and should be used with caution for the pri-
mary identification of reflex syncope. Since tilt protocols com-
monly used in adults may lack specificity in teenagers, in one study,
a shorter tilt test duration of 10 min at 60 or 70 degrees was used
and showed a specificity of >85%.401
In young patients, syncope can rarely be the initial manifestation of
unusual but life-threatening conditions such as LQTS, Kearns–Sayre
syndrome (external ophthalmoplegia and progressive heart block),
Brugada syndrome, catecholaminergic polymorphic VT,
Wolff-Parkinson-White syndrome, ARVC, HCM, pulmonary arterial
hypertension, myocarditis, arrhythmia after repaired congenital heart
disease, and anomalous origin of a coronary artery.
Some aspects of the history can suggest a cardiac origin, and
should prompt cardiac evaluation.
• Family history: premature SCD at age <40 years and/or familial
heart disease.
• Known or suspected heart disease.
• Event triggers: loud noise, fright, and/or extreme emotional
stress.
• Syncope during exercise, including swimming.
• Syncope without prodromes, while supine or sleeping, or pre-
ceded by chest pain or palpitations.
6.2.2. Therapy
The therapeutic approach is the same as in adults. However, it should
be stressed that the effectiveness of pharmacological agents and tilt
training for recurrent reflex syncope is undetermined in the absence
of well-designed paediatric trials. Furthermore, even in the presence
of VVS with prolonged asystole, pacemakers should be avoided due
to the relatively transient and benign nature of the syndrome.402
In summary, the key points for the evaluation of syncope in paedi-
atrics are as follows:
• Syncope in childhood is common, the majority being of reflex
origin, with only a minority having a potentially life-threatening
cause.
• Discriminating benign from serious causes is made primarily by
history, physical examination, and ECG results.
• Children with a history suggesting VVS, a normal ECG, and no
family history of arrhythmia should not undergo further cardiac
investigations.
• The cornerstone of therapy for young patients with reflex syn-
cope includes education and reassurance.
7. Psychogenic transient loss of
consciousness and its evaluation
In psychogenic TLOC there is no gross somatic brain dysfunction,
but the attacks fulfil the criteria for TLOC (see section 3.1). There
are two types: PPS and PNES. In PPS movements are absent, so
PPS resembles syncope or longer-lasting LOC, whereas in PNES
impressive limb movements mean the attacks resemble epileptic
seizures. PPS and PNES differ pathophysiologically from the
TLOC forms that they resemble: in PPS, BP and HR are normal or
high rather than low, and the EEG is normal instead of showing
the slowing or flattening typical of syncope; in contrast to epileptic
seizures, the EEG in PNES shows no epileptiform brain activity
during an attack.9,116
The frequency of PPS and PNES probably depends on the
setting. The rate of PPS varies from 1% of patients referred to
general syncope clinics94 to 8% of patients referred to specialist
neurological clinics,116 but PPS is probably insufficiently
recognized.154
7.1 Diagnosis
7.1.1 Historical criteria for attacks
The presence of a psychological trauma is not a prerequisite for a
diagnosis of conversion. The diagnosis of PPS rests on positive clues
taken from the patient’s history and from documenting normal EEG
results, HR, or BP during an attack. History taking in PPS usually
reveals a combination of the following features116,154,403:
(1) In most cases, the duration of PPS is as short as in syncope, but a
much longer duration is a useful diagnostic finding: patients may lie
immobile on the floor for 15–30 min.
(2) The eyes are usually open in epileptic seizures and syncope but are
usually closed in psychogenic TLOC.
(3) The attack frequency is high, with several attacks occurring over a
week or in a day.
(4) There is usually no recognisable trigger, and no sweating, pallor, or
nausea beforehand.
(5) Injury does not exclude PNES or PPS.
These features should occur together in most attacks. The pres-
ence of another pattern of features suggesting a true syncope type,
usually VVS, does not argue against a diagnosis of PPS.
7.1.2 Documentation of key features during an attack
The following features are relevant during an attack:
• Video recording or clinical observation, including provocation of
an attack during tilt testing. Primary features: sleep-like body posi-
tion with closed eyes and lack of response to speech or touch, if
ESC Guidelines 47
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tested. Secondary features: subtle signs incompatible with LOC
such as eyelid flicker, eyeball movements, swallowing, intact
muscle tone, normal movements absent in true unconsciousness,
and resistance to eye opening.
• BP: normal or elevated during TLOC.
• EEG: normal waking eye-closed EEG pattern, i.e. usually with
alpha activity, during TLOC.
The gold standard for PPS is documenting an attack with a home
video recorder or with a tilt testing during which BP, HR, and EEG
are normal.116,204,404 The gold standard for PNES is documenting an
attack with video-EEG monitoring.204,404
7.1.2.1 Management of psychogenic pseudosyncope
Announcing a psychological diagnosis to patients may be considered
difficult, but is necessary for reasons of honesty and as the first step of
treatment.404 It should be done by the somatic specialist who diagnoses
PPS.116,404 Important aspects are to assure patients that they are taken
seriously and that attacks are as involuntary as syncope or an epileptic
seizure. Acceptance of the diagnosis by patients may be critical for ther-
apy. In one observational study,405 communicating and explaining the
diagnosis resulted in an immediate reduction of attack frequency, with
39% of patients being asymptomatic during a mean follow-up period of
4 years. Some advice on how to inform the patient is provided in Web
Practical Instructions section 10: European Society of Cardiology information
sheet for patients affected by psychogenic pseudosyncope.
Cognitive behavioural therapy is the usual treatment of PNES and
PPS, if attacks remain present after explanation. One pilot random-
ized treatment trial, conducted in PNES,406 showed that psychologi-
cal therapy provided more attack reduction than no treatment or
treatment with sertraline. There are currently no trials on PPS.
8. Neurological causes and mimics
of syncope
This section discusses neurological disorders causing syncope or
resembling it, and tests to be performed in patients with syncope.
8.1 Clinical conditions
8.1.1 Autonomic failure
Neurological evaluation should be considered in OH due to auto-
nomic failure. Warning signs are early impotence, disturbed micturi-
tion, hyposmia, rapid eye movement, sleep behaviour
disorders,408,409 Parkinsonism, ataxia, cognitive impairment, and sen-
sory deficits. A multidisciplinary approach may be required in secon-
dary autonomic failure and in drug-induced OH, depending on the
underlying disease.
8.1.2 Epilepsy and ictal asystole
Table 10 provides a number of clues that aid the differentiation of
syncope from epileptic seizures.9,50,410,411 Epilepsy and syncope
may evoke one another on rare occasions, resulting in epileptic
seizures triggering syncope as well as syncope triggering an epilep-
tic seizure. The first form concerns ictal asystole. Whereas approx-
imately 90% of all epileptic seizures are accompanied by
tachycardia, ictal bradycardia and asystole occur in 0.3–0.5% of
seizures.412,413 Bradycardia precedes asystole and AV block may
occur, resembling the ECG pattern of reflex syncope.412,414
Epileptic asystole occurs during partial complex seizures, not dur-
ing generalized seizures. Epileptic asystole occurs in only a fraction
of the seizures of one person, and then occurs after a variable
interval of 5–100 s from seizure onset.415,416 If asystole lasts for
more than about 8 s, syncope ensues.416 A typical history is for a
partial complex seizure to progress as usual for that patient, and
then the patient suddenly falls flaccidly, with or without brief myo-
clonic jerking.416,417 Ictal bradycardia, asystole, and ictal AV block
are likely self-terminating,412 and are due to vagal activation
brought about by the seizure. Cessation of cortical activity due to
syncopal cerebral hypoperfusion will end the seizure. Therapy
requires anti-epileptic drugs and possibly a pacemaker.418
Ictal asystole is probably not involved in sudden death in epilepsy,
as this typically occurs in patients after unwitnessed nocturnal
generalized tonic-clonic seizures, i.e. another type of epi-
lepsy.414,419 Note that most cases of sudden cardiac arrest in
patients with epilepsy are due to cardiovascular disease and not to
ictal asystole.420
The second form concerns a syncopal epileptic seizure.
Hypoxia can trigger epileptic seizures.208,421 Such syncopal epilep-
tic seizures have been described in infants with reflex syncope
or cyanotic breath-holding spells. A typical syncopal spell
suddenly transforms into prolonged clonic movements that
last for minutes; note that shorter epileptic seizures may remain
unnoticed.
8.1.3 Cerebrovascular disorders
In general, a TIA concerns a focal neurological deficit without LOC,
and syncope the opposite. Subclavian steal refers to the rerouting of
blood flow to the arm through the vertebral artery due to proximal
Diagnosis and management of psychogenic
pseudosyncope
Recommendations Classa Levelb
Diagnosis
The recording of spontaneous attacks with
a video by an eyewitness should be consid-
ered for diagnosis of PPS.116,154
IIa C
Tilt testing, preferably with concurrent EEG
recording and video monitoring, may be
considered for diagnosis of PPS.116,403,407
IIb C
Management
Doctors who diagnose PPS should present
the diagnosis of PPS to the patient.116,404
IIa C
Cognitive behavioural therapy may be con-
sidered in the treatment of PPS if attacks
persist after explanation.
IIb C
EEG = electroencephalogram; PPS = psychogenic pseudosyncope.
aClass of recommendation.
bLevel of evidence.
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..stenosis or occlusion of the subclavian artery. A TIA may occur when
flow through the vertebral artery cannot supply both the arm and
part of the brain during forceful use of the arm. Steal most often
affects the left side. When detected with ultrasound, steal is asympto-
matic in 64% of cases.422 A TIA is likely due to steal only when it is
vertebrobasilar (see below) and associated with exercise of one arm.
There are no reliable reports of isolated LOC without focal neuro-
logical symptoms and signs in subclavian steal.
A TIA related to a carotid artery does not usually cause TLOC. An
exception concerns orthostatic TIAs, concerning a combination of
multiple stenoses of cerebral arteries and OH. This may rarely result
in repetitive, orthostatic, short-lasting, and stereotyped TIAs.423,424
A TIA of the vertebrobasilar system can cause LOC, but there are
always focal signs, usually limb weakness, gait and limb ataxia, vertigo,
diplopia, nystagmus, dysarthria, and oropharyngeal dysfunction.
Fewer than 1% of patients with vertebrobasilar ischaemia present
with a single presenting symptom.425
8.1.4 Migraine
Syncope, presumable VVS, and orthostatic intolerance occur more
often in patients with migraine, who have a higher lifetime prevalence
of syncope and often frequent syncope.426 In migraineurs, syncope
and migraine attacks rarely occur simultaneously.
Table 10 Differentiating syncope from epileptic seizures9,50,410,411
Clinical feature Syncope Epileptic seizures
Useful features
Presence of trigger Very often Rare
Nature of trigger Differs between types: pain, standing, emo-
tions for VVS; specific trigger for situational
syncope; standing for OH
Flashing lights is best known; also range of rare
triggers
Prodromes Often presyncope (autonomic activation in
reflex syncope, light-headedness in OH, palpi-
tations in cardiac syncope)
Epileptic aura: repetitive, specific for each patient.
Includes de´ja vu. Rising sensation in the abdomen
(epigastric aura) and/or an unusual unpleasant
smell
Detailed characteristics of
myoclonus
• <10, irregular in amplitude, asynchronous,
asymmetrical
• Starts after the onset of LOC
• 20–100, synchronous, symmetrical, hemilateral
• The onset mostly coincides with LOC
• Clear long-lasting automatisms as chewing or lip
smacking at the mouth
Tongue bite Rare, tip of tongue Side of tongue (rarely bilateral)
Duration of restoration of
consciousness
10–30 seconds May be many minutes
Confusion after attack No understanding of situation for <10 seconds
in most syncope, full alertness and awareness
afterwards
Memory deficit, i.e. repeated questions without
imprinting for many minutes
Features of limited utility
Incontinence Not uncommon Common
Presence of myoclonus (see below
for nature of myoclonus)
Very often 60%, dependent on accuracy of observation
Eyes open during LOC Frequent Nearly always
Fatigue and sleep afterwards Common, particularly in children Very common
Blue face Rare Fairly often
LOC = loss of consciousness; OH = orthostatic hypotension; VVS = vasovagal syncope.
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8.1.5 Cataplexy
Cataplexy concerns paresis or paralysis triggered by emotions, usu-
ally laughter, but also by a range of other triggers.427 Patients are con-
scious even when considered unconscious by eyewitnesses, and
there is no amnesia. Cataplexy is a key feature of narcolepsy; other
cardinal symptoms are excessive daytime sleepiness, sleep-onset
paralysis, and hypnagogic hallucinations. Cataplexy may be mistaken
for syncope, but also for PPS: a partial awareness of events may be
present in PPS, and the falls of cataplexy are partly controlled because
paralysis need not be immediately complete.
8.1.6 Drop attacks
The term drop attacks is confusing as it is variably used for
Menie`re’s disease, atonic epileptic seizures, and unexplained
falls.387 A specific condition also labelled drop attacks concerns
middle-aged women (rarely men) who suddenly find themselves
falling.428 They usually remember hitting the floor and can stand
up immediately afterwards.
8.2 Neurological tests
A schematic comprehensive figure of neurological tests used for
autonomic failure is shown in Figure 17.
8.2.1 Electroencephalography
The results of interictal EEGs are normal in syncope.410,430 An interic-
tal normal EEG cannot rule out epilepsy and the EEG in epilepsy
must always be interpreted in a clinical context. An EEG is not rec-
ommended when syncope is the most likely cause of TLOC, but it is
when epilepsy is the likely cause or when clinical data are equivocal.
The EEG is also useful to establish PPS, if recorded during a provoked
attack.
8.2.2 Brain computed tomography and magnetic
resonance imaging
Computed tomography and MRI in uncomplicated syncope should
be avoided. If neurological examination points out Parkinsonism,
ataxia, or cognitive impairment, MRI is recommended. In cases of
contraindication for MRI, computed tomography is recommended to
exclude brain lesions.
8.2.3 Neurovascular studies
No studies suggest that carotid Doppler ultrasonography is valuable
in patients with typical syncope.
8.2.4 Blood tests
An acute or subacute onset of multidomain autonomic failure sug-
gests a paraneoplastic or autoimmune cause. Screening for specific
paraneoplastic antibodies is recommended: the most common para-
neoplastic antibodies are anti-Hu, while others are anti-Purkinje cell
cytoplasmic autoantibody type 2 and anti-collapsin response media-
tor protein 5.431 Seropositivity for any of the above-mentioned anti-
bodies may therefore prompt further investigation for occult
malignancy (e.g. whole-body fluorodeoxyglucose-positron emission
tomography).432
Seropositivity for antiganglionic acetylcholine receptor
antibodies is the serological hallmark of autoimmune autonomic
ganglionopathy.433,434
9. Organizational aspects
9.1 Syncope (transient loss of
consciousness) management unit
Since the publication of the 2009 ECS Guidelines, the EHRA Task
Force has published a further position statement on the rationale and
requirement for syncope units.63 The position paper offers a prag-
matic approach to the rationale and requirement for a syncope unit.
It is addressed to physicians and others in administration who are
Neurological evaluation
Recommendations Classa Levelb
Neurological evaluation is indicated
when syncope is due to autonomic fail-
ure to evaluate the underlying disease.
I C
Neurological evaluation is indicated in
patients in whom TLOC is suspected to
be epilepsy.
I C
TLOC = transient loss of consciousness.
aClass of recommendation.
bLevel of evidence.
Neurological tests
Recommendations Classa Levelb
Brain MRI is recommended if neurological
examination indicates Parkinsonism, ataxia,
or cognitive impairment.
I C
Screening for paraneoplastic antibodies and
antiganglionic acetylcholine receptor anti-
bodies is recommended in cases of acute or
subacute onset of multidomain autonomic
failure.432,433
I B
EEG, ultrasound of neck arteries, and com-
puted tomography or magnetic resonance
imaging of the brain are not indicated in
patients with syncope.178,435–440
III B
Additional advice and clinical perspectives
Seropositivity for any paraneoplastic antibody or for antigan-
glionic acetylcholine receptor antibodies should prompt further
investigations for occult malignancy.
EEG = electroencephalogram; MRI = magnetic resonance imaging.
aClass of recommendation.
bLevel of evidence.
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..interested in establishing a syncope unit in their hospital so that they
can meet the standards proposed by the ESC, the EHRA, and the
Heart Rhythm Society. The following is the context and evidence for
recommendations regarding syncope units (Table 11).
9.1.1 Definition of a syncope unit
A syncope unit is a facility featuring a standardized approach to the
diagnosis and management of TLOC and related symptoms, with
dedicated staff and access to appropriate diagnostics and therapies.
Figure 17 Diagnostic work-up of cardiovascular autonomic failure (adapted from Fanciulli et al.429). CNS = central nervous system; CRMP-5 =
collapsin response mediator protein 5; DAT = dopamine active transporter; HbA1c = haemoglobin A1c; HIV = human immunodeficiency virus; 123I-
MIBG = 123I-metaiodobenzylguanidine; MRI = magnetic resonance imaging; PCA-2 = Purkinje cell cytoplasmic autoantibody type 2; SPECT = single-
photon emission computed tomography; SS-A = Sjogren’s syndrome-associated antigen A; SS-B = Sjogren’s syndrome-associated antigen B.
Table 11 Key components of a syncope unit
• The syncope unit should take the lead in service delivery for syncope, and in education and training of healthcare professionals who encounter syncope.
• The syncope unit should be led by a clinician with specific knowledge of TLOC and additional necessary team members (i.e. clinical nurse special-
ist) depending on the local model of service delivery.
• The syncope unit should provide minimum core treatments for reflex syncope and OH, and treatments or preferential access for cardiac syn-
cope, falls, psychogenic pseudosyncope, and epilepsy.
• Referrals should be directly from family practitioners, EDs, in-hospital and out-hospital services, or self-referral depending on the risk stratifica-
tion of referrals. Fast-track access, with a separate waiting list and scheduled follow-up visits, should be recommended.
• Syncope units should employ quality indicators, process indicators, and desirable outcome targets.
ED = emergency department; OH = orthostatic hypotension; TLOC = transient loss of consciousness.
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9.1.2 Definition of syncope specialist
The syncope specialist is defined as one who has responsibility for
the comprehensive management of the patient from risk stratification
to diagnosis, therapy, and follow-up, through a standardized protocol.
A syncope specialist is a physician who has sufficient knowledge of
historical clues and physical findings to recognize all major forms of
TLOC, including mimics, as well as syndromes of orthostatic
intolerance.
9.1.3 Goal of a syncope unit
Although the benefit of a syncope unit or a syncope specialist in the
different healthcare systems has not been exposed to rigorous
scientific or economic scrutiny, the consensus is that a dedicated
service (a syncope unit) affords better management of TLOC, from
risk stratification to diagnosis, therapy, and follow-up, and better edu-
cation and training of stakeholders. Further research is likely to have
an important impact on our confidence in the estimate of effect.
9.1.4 Model of a syncope unit
The syncope unit should provide minimum core treatments for
reflex syncope and OH, and treatments or preferential access for
cardiac syncope, falls, psychogenic syncope, and epilepsy (Table 12).
The tests and assessments available in the syncope unit are detailed
in Table 13.
Table 12 Structure of the syncope unit
Staffing of a syncope unit is composed of:
(1) One or more physicians of any specialty who are syncope specialists. Owing to the multidisciplinary nature of TLOC management, each syn-
cope unit should identify specific specialists for the syncope unit and for consultancies.
(2) A staff comprising professionals who will advance the care of patients with syncope. These may be physicians, specialized nurses, or others who
bring multidisciplinary skills to the facility, coupled with administrative support. The roles played by members of the team may vary according to
local circumstances and individual skill. Nurses may be expected to take very important roles including initial assessment, follow-up clinic evalua-
tion, selection of investigations (including tilt testing), and implantation/insertion of ECG loop recorders according to predefined protocols and
local regulations (see Table 14).
(3) Given that the syncope unit is integrated within a hospital organization, syncope specialists and staff are not necessarily employed full-time, but
frequently have other duties depending on the volume of activity in the unit.
Facility, protocol, and equipment
(1) A syncope unit will deliver most of its care to outpatients in addition to ED and inpatients.
(2) The syncope unit should follow an internal protocol, which applies to diagnosis and management and is agreed by stakeholders.
(3) An equipped facility must be available.
(4) Essential equipment/tests:
- 12-lead ECG and 3-lead ECG monitoring
- Non-invasive beat-to-beat BP monitor with recording facilities for subsequent analysis
- Tilt-table
- Holter monitors/external loop recorders
- ILRs
- Follow-up of ILRsa
- 24-hour BP monitoring
- Basic autonomic function tests.
(5) Established procedures for:
- Echocardiography
- EPS
- Stress test
- Neuroimaging tests.
(6) Specialists’ consultancies (cardiology, neurology, internal medicine, geriatric, psychology), when needed.
Therapy
Patients with syncope will receive their therapy under the care of the syncope unit unless expertise outside that of the unit is required.
Database management
The syncope unit is required to keep medical records that should also include follow-up when appropriate. The database will also offer the possibil-
ity of collaborative research with other syncope units.
BP = blood pressure; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ILR = implantable loop recorder;
TLOC = transient loss of consciousness.
aImplantation of loop recorders may be performed either by syncope unit physicians or by external cardiologists at the request of the syncope unit physicians.
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9.1.5 Access and referrals to a syncope unit
Referral can be direct from family practitioners, EDs, in-hospital and
out-hospital services, or self-referral from the patient. Fast-track
access with a separate waiting list and scheduled follow-up visits is
recommended. In particular, patients at low/intermediate risk admit-
ted to the ED should benefit from such fast-track facilities (so-called
protected discharge or advanced access with an appointment for
early assessment) to reduce hospitalization rates, directly from the
ED or after a short stay in the short observation unit of the ED (see
section 4.1.2).
9.1.6 Outcomes and quality indicators
The EHRA Task Force63 has developed the following preliminary
quality indicators, based on consensus, as a rough guide for
practitioners:
(1) Absolute rate of undiagnosed TLOC should be reduced by 20%;
(2) Less than 20% of low-/intermediate-risk TLOC patients should be
admitted from the ED;
(3) The syncope unit should have a 20% reduction in costs relative
to usual practice and improved outcomes (i.e. <5% readmissions
for syncope and <20% of paced patients with recurrence at
1 year).
9.2 The clinical nurse specialist in the
syncope unit
9.2.1 Definition
The syncope unit clinical nurse specialist is defined as an experienced
practitioner who has sufficient knowledge of history features and
physical findings to recognize all major forms of TLOC, as well as syn-
dromes of orthostatic intolerance. The clinical nurse specialist should
work in close collaboration with the syncope specialist. The core
competencies of the clinical nurse specialist include a specialized clini-
cal focus, patient advocacy, education and training, auditing, research,
and inter- and intradisciplinary consultations.
9.2.2 Role and skills of the clinical nurse specialist
The clinical nurse specialist should be skilled in the performance and
interpretation of structured history taking, 12-lead ECG and routine
blood test results, tilt testing, active stand tests, autonomic function
tests, ECG monitoring (Holter and/or external loop recorder),
ABPM, ILR monitoring, and subsequent triaging of patients and moni-
toring responses to therapy. Other skills will depend on the service
model, e.g. pacemaker interrogation. The clinical nurse specialist may
have responsibility for follow-up clinics for cardiovascular risk factor
management, autonomic function testing and monitoring, manage-
ment (including education in PCM) of VVS and OH, and follow-up
Table 13 Test and assessments available in a syncope unit
Initial assessment
History and physical evaluation including 3-min orthostatic BP measurementa
12-lead standard ECG
Subsequent tests and assessments (only when indicated)
Blood tests Electrolytes, haemoglobin, troponin, B-type natriuretic peptide, glucose, D-dimer, haemogas anal-
ysis/oxygen saturation
Provocative tests CSM, tilt testing
Monitoring External loop recording, implantable loop recording, ambulatory 1–7 days ECG monitoring,
24–48-hour BP monitoring
Autonomic function tests Standing test, Valsalva manoeuvre, deep-breathing test, cold pressor test, and/or established pro-
cedures for access to other autonomic function tests
Cardiac evaluation Established procedures for access to echocardiogram, stress test, electrophysiological study, cor-
onary angiography
Neurological evaluation Established procedures for access to neurological tests (computed tomography, magnetic reso-
nance imaging, EEG, video-EEG)
Geriatric evaluation Established procedures for access to fall risk assessment (cognitive, gait and balance, visual, envi-
ronmental) and for gait and balance retraining
Psychological or psychiatric evaluation Established procedures for access to psychological or psychiatric consultancy (mental health
problem or psychogenic syncope)
BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram.
aPostural orthostatic tachycardia may require longer period of standing.
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..of external and internal loop and Holter monitors and ABPM63
(Table 14).
The clinical nurse specialist should be key in developing and deliv-
ering communication strategies and processes for the syncope unit
for all stakeholders—patients and practitioners—and play a pivotal
role in education and training together with the syncope specialist.
The clinical nurse specialist should be involved in regular auditing and
collection of data to inform quality indicators. See the video in Web
Practical Instructions section 11.
Although the skill mix of a clinical nurse specialist has not been
exposed to rigorous scientific or economic scrutiny, the consen-
sus is that the clinical nurse specialist should have the neces-
sary skills to deliver assessment and treatment for syncope and
TLOC. Further research is required to establish the benefits.
10. Key messages
The ESC Task Force has selected 19 simple rules to guide the diagno-
sis and management of syncope patients with TLOC according to the
2018 ESC Guidelines on syncope:
Diagnosis: initial evaluation
(1) At the initial evaluation answer the following four key questions:
Was the event TLOC?
 In cases of TLOC, are they of syncopal or non-syncopal origin?
 In cases of suspected syncope, is there a clear aetiological diagnosis?
 Is there evidence to suggest a high risk of cardiovascular events or
death?
(2) At the evaluation of TLOC in the ED, answer the following three
key questions:
 Is there a serious underlying cause that can be identified?
Table 14 The role of physicians and staff in performing procedures and tests
Procedure or test Syncope unit
physician
Syncope
unit staff
Non-syncope
unit personnel
History taking X
Structured history taking (e.g. application of software technologies and algorithms) X
12-lead ECG X
Blood tests X
Echocardiogram and imaging X
CSM X
Active standing test X
Tilt testing (X)a X
Basic autonomic function test X
ECG monitoring (Holter, external loop recorder): administration and interpretation X X
ILR X (X)b
Remote monitoring X
Other cardiac tests (stress test, EPS, angiograms) X
Neurological tests (computed tomography, magnetic resonance imaging, EEG, video-EEG) X
Pacemaker and ICD implantation, catheter ablation X
Patient education, biofeedback training,c and instruction sheet on PCM X X
Final report and clinic note X
Communication with patients, referring physicians, and stakeholders. X X
Follow-up X X
BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram; EPS = electrophysiological study; ICD = implantable cardioverter
defibrillator; ILR = implantable loop recorder; PCM = physical counter-pressure manoeuvres.
aPhysician need not be in the room, but a physician adequately trained in resuscitation needs to be in the vicinity of the test.
bCurrent practice limited to a few countries.
cBiofeedback means that the PCM training session consists of biofeedback training using a continuous BP monitor. Each manoeuvre is demonstrated and explained. The manoeu-
vres are practised under supervision, with immediate feedback of the recordings to gain optimal performance.
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. If the cause is uncertain, what is the risk of a serious outcome?
 Should the patient be admitted to hospital?
(3) In all patients, perform a complete history taking, physical examina-
tion (including standing BP measurement), and standard ECG.
(4) Perform immediate ECG monitoring (in bed or telemetry) in high-
risk patients when there is a suspicion of arrhythmic syncope.
(5) Perform an echocardiogram when there is previous known heart
disease, or data suggestive of structural heart disease or syncope
secondary to cardiovascular cause.
(6) Perform CSM in patients >40 years of age with syncope of unknown
origin compatible with a reflex mechanism.
(7) Perform tilt testing in cases where there is suspicion of syncope due
to reflex or an orthostatic cause.
(8) Perform blood tests when clinically indicated, e.g. haematocrit and
cell blood count when haemorrhage is suspected, oxygen saturation
and blood gas analysis when hypoxic syndromes are suspected, tro-
ponin when cardiac ischaemia-related syncope is suspected, and D-
dimer when pulmonary embolism is suspected, etc.
Diagnosis: subsequent investigations
9. Perform prolonged ECG monitoring (external or implantable) in
patients with recurrent severe unexplained syncope who have all of
the following three features:
 Clinical or ECG features suggesting arrhythmic syncope.
 A high probability of recurrence of syncope in a reasonable time.
 Who may benefit from a specific therapy if a cause for syncope is
found.
10. Perform EPS in patients with unexplained syncope and bifascicular
BBB (impending high-degree AV block) or suspected tachycardia.
11. Perform an exercise stress test in patients who experience syncope
during or shortly after exertion.
12. Consider basic autonomic function tests (Valsalva manoeuvre and
deep-breathing test) and ABPM for the assessment of autonomic
function in patients with suspected neurogenic OH.
13. Consider video recording (at home or in hospital) of TLOC sus-
pected to be of non-syncopal nature.
Treatment
14. To all patients with reflex syncope and OH, explain the diagnosis,
reassure, explain the risk of recurrence, and give advice on how to
avoid triggers and situations. These measures are the cornerstone of
treatment and have a high impact in reducing the recurrence of
syncope.
15. In patients with severe forms of reflex syncope, select one or more of
the following additional specific treatments according to the clinical
features:
 Midodrine or fludrocortisone in young patients with low BP
phenotype.
 Counter-pressure manoeuvres (including tilt training if needed) in
young patients with prodromes.
 ILR-guided management strategy in selected patients without
or with short prodromes.
 Discontinuation/reduction of hypotensive therapy targeting a
systolic BP of 140 mmHg in old hypertensive patients.
 Pacemaker implantation in old patients with dominant
cardioinhibitory forms.
16. In patients with OH, select one or more of the following additional
specific treatments according to clinical severity:
 Education regarding lifestyle manoeuvres.
 Adequate hydration and salt intake.
 Discontinuation/reduction of hypotensive therapy.
 Counter-pressure manoeuvres.
 Abdominal binders and/or support stockings.
 Head-up tilt sleeping.
 Midodrine or fludrocortisone.
17. Ensure that all patients with cardiac syncope receive the specific ther-
apy of the culprit arrhythmia and/or of the underlying disease.
18. Balance the benefits and harm of ICD implantation in patients with
unexplained syncope at high risk of SCD (e.g. those affected by left
ventricle systolic dysfunction, HCM, ARVC, or inheritable arrhyth-
mogenic disorders). In this situation, unexplained syncope is defined as
syncope that does not meet any class I diagnostic criterion defined in
the tables of recommendations of the 2018 ESC Guidelines on syn-
cope and is considered a suspected arrhythmic syncope.
19. Re-evaluate the diagnostic process and consider alternative therapies
if the above rules fail or are not applicable to an individual patient.
Bear in mind that Guidelines are only advisory. Even though they are
based on the best available scientific evidence, treatment should be
tailored to an individual patient’s need.
11. Gaps in evidence and areas for
future research
Clinicians responsible for managing patients with TLOC must fre-
quently make treatment decisions without adequate evidence or a
consensus of expert opinion. The following is a short list of selected,
common issues that deserve to be addressed in future clinical
research.
Diagnosis: the gap between the best
available scientific evidence and the need
for the dissemination of these concepts
into clinical practice
There is wide variation in the practice of syncope evaluation, and
wide variation in the adoption of recommendations from pub-
lished guidelines. The absence of a systematic approach to TLOC
incurs higher health and social care costs, unnecessary hospitaliza-
tions and diagnostic procedures, prolongation of hospital stays,
lower diagnostic rates, and higher rates of misdiagnoses and symp-
tom recurrence.
Therefore, there is a need for:
1) Large clinical studies that assess the diagnostic yield and compliance of a
guideline-based standardized systematic approach
Despite the recommendation from the ESC Guidelines on syncope,
syncope units are not widely established in clinical practice. Barriers to
establishing a syncope unit include lack of resources, lack of trained
dedicated staff, and complex presentations to multiple settings, necessi-
tating involvement from multiple disciplines. The evidence for the use-
fulness of syncope units is controversial.
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2) Large clinical studies that test the superiority of management in a dedicated
syncope facility vs. conventional management
Diagnosis: the need for new diagnostic
tests and devices
BP recording is crucial for the majority of clinical TLOC situations
and will yield important information for the treatment of syncope.
Unfortunately, current long-term BP (or surrogate) recording sys-
tems are not optimal for diagnostic use in the syncope evaluation
setting.
Therefore, there is a need for:
3) Development and validation of new diagnostic multiparametric devices that
can record heart rhythm and BP (and possibly other physiological parameters
such as cerebral saturation or EEG) at the time of a syncopal event.
Treatment: lack of evidence of efficacy of
most available therapies
Only a few small RCTs have been conducted on treatment of syncope.
In addition, syncopal recurrences are unpredictable and often decrease
spontaneously after medical assessment, even in the absence of a specific
therapy. The consequence of the spontaneous decrease is that any ther-
apy for syncope prevention appears to be more effective than it actually
is, making the results of observational data on therapy questionable in
the absence of a control group. No therapy can be effective for all
patients. Any therapy should be assessed in homogeneous subgroups.
Therefore, there is strong urgent need for RCTs on the efficacy of:
4) Pharmacological therapies targeted to specific subgroups of reflex syncope.
5) Pacemaker therapy targeted to specific subgroups of cardioinhibitory reflex
syncope.
6) Pharmacological therapies of OH-mediated syncope.
7) ICD therapy targeted to specific subgroups of patients with unexplained syn-
cope at risk of SCD.
Treatment: the need for new therapies
There is a need to move towards personalized medicine. Improving
our knowledge of the biochemical mechanisms underlying specific
forms of reflex syncope will allow the development of new therapies
in such specific settings. For example, a low adenosine phenotype
and a low norepinephrine phenotype have been recently identified.
Therefore, there is a need for:
8) Randomized clinical trials on the efficacy of theophylline (and other xantine
antagonists) for low adenosine syncope and norepinephrine transport inhibi-
tors for low epinephrine syncope.
Syncope is a transient phenomenon. The ideal therapy should be
one that is administered only when needed.
Therefore, there is a need for:
9) Randomized clinical trials of on-demand administration of specific therapy
based on specific sensors similar to adrenalin injectors in asthma or nasal
spray for paroxysmal SVT.
Recommendations Class Level
Diagnostic criteria with initial evaluation
VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive pro-
drome (pallor, sweating, and/or nausea).8,13–17
I C
Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers listed in Table 3.8,13–17 I C
Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant OH.18–24 I C
Arrhythmic syncope is highly probable when the ECG shows25–39:
• Persistent sinus bradycardia <40 b.p.m. or sinus pauses >3 s in the awake state and in the absence of physical training.
• Mobitz II second- and third-degree AV block.
• Alternating left and right BBB.
• VT or rapid paroxysmal SVT.
• Non-sustained episodes of polymorphic VT and long or short QT interval.
• Pacemaker or ICD malfunction with cardiac pauses.
I C
Continued
12. ‘What to do’ and ‘what not to do’ messages from the Guidelines
56 ESC Guidelines
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy037/4939241
by Universita' Degli Studi di Firenze user
on 19 March 2018
Management of syncope in the ED
It is recommended that patients with low-risk features, likely to have reflex or situational syncope or syncope due to OH,
are discharged from the ED.27,35,36,49–54,58,62,69
I B
It is recommended that patients with high-risk features receive an early intensive prompt evaluation in a syncope unit or in
an ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76
I B
It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit
instead of being hospitalized.40,63–65,77
I B
CSM
CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 I B
CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduces spontaneous symptoms, and
patients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102
I B
Active standing
Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-
cated at initial syncope evaluation.20,103,104
I C
Syncope due to OH is confirmed when there is a fall in systolic BP from a baseline value >_20 mmHg, diastolic BP >_10
mmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104
I C
ECG monitoring
Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). I C
ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk
criteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202,
Supplementary Data Table 5
I A
ILR is indicated in high-risk (criteria listed in Table 6) patients in whom a comprehensive evaluation did not demonstrate a
cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary prevention ICD
or pacemaker indication.174,180,187,188,195, Supplementary Data Tables 5 and 6
I A
Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-
rhythmia) is detected.172,184–186,188,200 I B
EPS
In patients with syncope and previous myocardial infarction or other scar-related conditions, EPS is indicated when syncope
remains unexplained after non-invasive evaluation.218
I B
In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V
interval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological
challenge.188,214–217,221
I B
In patients with unexplained syncope and previous myocardial infarction or other scar-related conditions, it is recom-
mended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46
I B
In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that
the induction of rapid SVT or VT, which reproduces hypotensive or spontaneous symptoms, is managed with appropriate
therapy according to the current ESC Guidelines.46,222
I C
Echocardiography
Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 I B
Exercise testing
Exercise testing is indicated in patients who experience syncope during or shortly after exertion. I C
Syncope due to second- or third-degree AV block is confirmed when the AV block develops during exercise, even without
syncope.253–257
I C
Reflex syncope is confirmed when syncope is reproduced immediately after exercise in the presence of severe hypotension.250–252 I C
Continued
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13. Supplementary Data and Web
Practical Instructions
Supplementary Data with additional Web Tables complementing the
full text, and an additional Web Practical Instructions document—
with a glossary containing definitions of syncope and related concepts
with tracings, videos, flow charts, and checklists—are available on the
European Heart Journal website and via the ESC Website at www.
escardio.org/guidelines.
14. Appendix
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Stefan Agewall (Norway), Emanuele Barbato (Italy), He´ctor Bueno
(Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan
Mircea Coman (Romania), Veronica Dean (France), Victoria Delgado
(The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli
(Switzerland), Gerhard Hindricks (Germany), Bernard Iung
(France), Peter Ju¨ni (Canada), Hugo Albert Katus (Germany), Juhani
Treatment of reflex syncope
Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-
gers and situations are indicated in all patients. Supplementary Data Table 10
I B
Beta-adrenergic blocking drugs are not indicated.279,280 III A
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.299,300 III B
Treatment of OH
Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-
gers and situations are indicated in all patients.
I C
Adequate hydration and salt intake are indicated.310,311 I C
Treatment of syncope due to cardiac arrhythmias
Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic
bradycardia.200,210–212,255,334–338,341
I B
Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including
AF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECG.
I C
Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C
Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 I B
Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence. I C
An ICD is indicated in patients with syncope due to VT and ejection fraction <_35%.46 I A
An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS.218 I C
ICD indications in patients with unexplained syncope and left ventricular systolic dysfunction
ICD therapy is recommended to reduce SCD in patients with symptomatic heart failure (NYHA class II–III) and LVEF
<_35% after >_3 months of optimal medical therapy, who are expected to survive for >_1 year with good functional status.46
systolic dysfunction
I A
Syncope in patients with comorbidity and frailty
A multifactorial evaluation and intervention is recommended in older patients because more than one possible cause for
syncope and unexplained fall may be present.33,372–374,376–380
I B
Neurological evaluation
Neurological evaluation is indicated when syncope is suspected to be epilepsy or due to autonomic failure to evaluate the
underlying disease.
I C
AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; BP = blood pressure; b.p.m. = beats per minute; CSM = carotid sinus massage; CSS = carotid sinus syn-
drome; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ESC = European Society of Cardiology; HR = heart rate; ICD = implantable
cardioverter defibrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OH = orthostatic hypotension;
SCD = sudden cardiac death; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VT = ventricular tachycardia; VVS = vasovagal syncope.
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Knuuti (Finland), Patrizio Lancellotti (Belgium), Christophe
Leclercq (France), Theresa McDonagh (UK), Massimo Francesco
Piepoli (Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece),
Marco Roffi (Switzerland), Evgeny Shlyakhto (Russia), Miguel Sousa-
Uva (Portugal), Iain A. Simpson (UK), Jose Luis Zamorano (Spain).
ESC National Cardiac Societies actively involved in the review
process of the 2018 ESC Guidelines for the diagnosis and
management of syncope:
Austria: Austrian Society of Cardiology, Franz Xaver Roithinger;
Belarus: Belorussian Scientific Society of Cardiologists, Alexandr
Chasnoits; Belgium: Belgian Society of Cardiology, Yves
Vandekerckhove; Bulgaria: Bulgarian Society of Cardiology, Vasil B.
Traykov; Croatia: Croatian Cardiac Society, Davor Puljevic;
Cyprus: Cyprus Society of Cardiology, Elias Papasavvas; Czech
Republic: Czech Society of Cardiology, Josef Kautzner; Denmark:
Danish Society of Cardiology, Henning Mølgaard; Egypt: Egyptian
Society of Cardiology, Mostafa Nawar; Finland: Finnish Cardiac
Society, Hannu Parikka; The Former Yugoslav Republic of
Macedonia: Macedonian FYR Society of Cardiology, Marija Vavlukis;
France: French Society of Cardiology, Olivier Piot; Georgia:
Georgian Society of Cardiology, Kakhaber Etsadashvili; Germany:
German Cardiac Society, Thomas Klingenheben; Greece: Hellenic
Society of Cardiology, Spyridon Deftereos; Hungary: Hungarian
Society of Cardiology, Laszlo Saghy; Iceland: Icelandic Society of
Cardiology, Kristjan Gudmundsson; Israel: Israel Heart Society, Roy
Beinart; Italy: Italian Federation of Cardiology, Antonio Raviele;
Kazakhstan: Association of Cardiologists of Kazakhstan, Ayan
Abdrakhmanov; Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin
Mirrakhimov, Latvia: Latvian Society of Cardiology, Oskars Kalejs;
Libya: Libyan Cardiac Society, Hisham A. Benlamin; Lithuania:
Lithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:
Luxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese
Cardiac Society, Mark A. Sammut; Moldova: Moldavian Society of
Cardiology, Aurica Raducan; Montenegro: Montenegro Society
of Cardiology, Mihailo Vukmirovic; Morocco: Moroccan Society of
Cardiology, Salima Abdelali; The Netherlands: Netherlands
Society of Cardiology, Martin E.W. Hemels; Norway: Norwegian
Society of Cardiology, Kristina H. Haugaa; Poland: Polish Cardiac
Society, Rafał Baranowski; Portugal: Portuguese Society of
Cardiology, Pedro Silva Cunha; Romania: Romanian Society of
Cardiology, Gheorghe-Andrei Dan; Russian Federation: Russian
Society of Cardiology, Tatyana Tyurina; San Marino: San Marino
Society of Cardiology, Luca Bertelli; Slovakia: Slovak Society of
Cardiology, Peter Mitro; Spain: Spanish Society of Cardiology,
Ignacio Fernandez Lozano; Sweden: Swedish Society of Cardiology,
Lennart Bergfeldt; Switzerland: Swiss Society of Cardiology, Stefan
Osswald; Tunisia: Tunisian Society of Cardiology and Cardio-
Vascular Surgery, Ben Halima Afef; Turkey: Turkish Society of
Cardiology, H. Murat €Ozdemır; United Kingdom: British
Cardiovascular Society, P. Boon Lim.
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